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1 Introduction 
1.1 Cancer worldwide and therapy options 
Malignant neoplasms were declared the leading cause of death (26.6%) in 
developed countries followed by heart (10.3%) and cerebrovascular diseases 
(9.4%) in 2004 (American Cancer Society, 2011). Estimates from the 
International Agency for Research on Cancer (IARC) formulated a number of 
new cancer cases of 12.667.500 million in 2008 worldwide. The number of total 
worldwide cancer deaths in 2008 was 7.6 million. The two most common types 
of cancer in women are breast cancer and cervix uteri carcinoma, the most 
common cancer cases in men are lung & bronchus carcinoma and prostate 
cancer (Farley et al., 2010). Both women and men are also affected by another 
type of malignancy: colorectal cancer. Colorectal cancer is one of the three 
most common tumors in both women and men worldwide (American Cancer 
Society, 2011). 
Some cancers can be detected and eradicated as precancerous lesions or early 
stage cancers due to successful screening methods, e.g. colorectal cancer 
(CRC). But in most cases an aggressive cancer therapy is the only possibility to 
extirpate the malignant cells. A common problem is the prevalence of metastatic 
lesions in case of already advanced stage disease at time of diagnosis. 15-20% 
of the patients suffering from CRC show metastasis at initial diagnosis, most 
frequently localized within the liver and secondly within the peritoneal cavity 
(LMU München, 2012). Peritoneal carcinosis is often combined with clinical 
symptoms and is likely to drastically reduce the quality of life. Moreover patients 
with peritoneal carcinosis were shown to often have a very short median 
survival (Sadeghi et al., 2000). 
The three common options for cancer treatment are surgery, chemotherapy and 
radiotherapy, which can be applied alone or in combination (Farley et al., 2010). 
Besides these three modalities there are several other treatment options 
available like hormone-therapy, monoclonal antibodies and small molecules. 
In case of peritoneal carcinosis, systemic chemotherapy and hyperthermic 
intraperitoneal chemotherapy (HIPEC) are the most common treatment options 
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(Glockzin et al., 2007) and surgery is used to treat frequent complications like 
stenosis or gastrointestinal bleeding. HIPEC enhances the local toxic effect 
while decreasing systemic toxic side effects. Peritonectomy (Sugarbaker, 2007), 
which is also called cytoreductive surgery (CRS), combined with intraperitoneal 
HIPEC enhanced the median survival of patients significantly (Esquivel et al., 
1993; Verwaal et al., 2003). It could be shown that macroscopic CRS led to a 
significant increase in survival (Glehen et al., 2004). Nevertheless, all these 
therapy options still remain mostly palliative in nature. 
It is well known that patients suffering from peritoneal carcinosis only benefit 
from a complete eradication of all tumor cells within the peritoneal cavity and 
not from a tumor debulking surgery (peritonectomy). The problem of incomplete 
tumor cell eradication also exists in other malignancies, e.g. sarcomas, which 
often resist first line therapy. 
At this point, alternative therapy modalities have to be strongly considered. 
Virotherapy represents one of these alternative therapy options. This “new” 
treatment option lately became more and more part of preclinical and clinical 
research and now seems to be waiting in the wings to enter the clinic as soon 
as first virotherapeutics will be approved by the regulatory authorities. 
 
1.2 Virotherapy as a novel treatment opportunity 
 
Figure 1. Oncolytic mechanism of a viral agent/virotherapeutic (Liu et al., 2004) 
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Virotherapy is the treatment of cancers using attenuated, replication-competent, 
and recombinant viral agents that selectively infect and kill cancer cells. Several 
mechanisms like the impact of viral replication within the cancer cells, a directly 
cytotoxic effect and the increasing viral load due to massive production of 
progeny virus particles lead to cell lysis (so-called oncolysis) and viral spread. 
Normal cells and healthy tissues around tumorous lesions are only marginally 
affected by viral cell killing. 
The first experiences with viruses showing oncolytic potency and tumor 
regression were noted in early case reports from the beginning of the 20th 
century. Tumor regression was observed after natural infection (Bluming et al., 
1971; Pasquinucci, 1971; Taqi et al.,1981) or was caused by viral vaccines 
(Greentree, 1983; Hansen et al., 1978). 
In the middle of the 20th century, cancer treatment with oncolytic wild type or 
vaccine viruses started and was directly followed by the treatment of cancer 
with engineered viruses showing a high selectivity for cancer cells. Finally, 
engineered armed viruses were used for treatment (Liu et al., 2004). Several of 
these oncolytic viruses have already entered clinical trials (Arakawa et al., 1987; 
Hamid et al., 2003; Nemunaitis et al., 2011). In a further step, virotherapy was 
combined in a widespread manner with chemotherapeutics such as 5-FU 
(Gnant et al., 1999) and radiotherapy (Ottolino-Perry et al., 2010). First 
promising results using combination therapies were published: The combination 
of chemotherapy and the oncolytic adenovirus ONYX-015 (Khuri et al., 2000), 
the combination of the vaccinia vector GLV-1h68 and cisplatin/gemcitabine (Yu 
et al., 2009) and the combination treatment with chemotherapeutics and an 
oncolytic HSV-agent (Kanai et al., 2010) have already shown quite encouraging 
results. 
The most important key data concerning virotherapy are safety and oncolytic 
efficiency, which are directly related to the modes of application, distribution, 
shedding and immune system-mediated elimination of the viral agent. In our 
studies we chose two viral vector systems which have an outstanding safety 
profile (Enders et al., 1954; Yu et al., 2009), provide several application 
modalities (Grote et al., 2011; Mastrangelo et al., 2000; Peng et al., 2002;) and 
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have already been successfully applied for the treatment of solid tumors in 
human xenograft animal models (Grote et al., 2001; Yu et al., 2007). One of 
these vectors is the 3rd generation vaccinia virus GLV-1h68, the other one is the 
recombinant measles virus MeV-SCD. To buy into Ivaylo Gentschev et al.: 
”Virotherapy using oncolytic vaccinia virus strains is one of the most promising 
new strategies for cancer therapy” oncolytic vaccinia virus strains is one of the 
most promising new strategies for cancer therapy.” (Gentschev et al., 2010). 
The understanding of vaccinia virus behaviour in humans due to the eradication 
of smallpox argues for the future clinical use of vaccinia virus-based viro-
therapeutics. Therefore, JX-594 (Jennerex Biotherapeutics), a targeted 
oncolytic poxvirus, was one of the first viral agents to be tested in preclinical 
and clinical trials (Kim et al., 2006; Park et al., 2008). MeV-SCD, a measles 
virus vaccine-based virotherapeutic vector, is the other promising tool derived 
from Edmonston B strain. This strain was used as an anti-measles vaccine in 
many parts of the world. The vaccine strains derived from the Edmonston B 
strain are known as Mérieux, Rouvax, Moraten, Lirugen, Morbilvax, Attenuvax, 
Mevilin, and Rimevax. The measles vaccines supplied through the World Health 
Organization's program on Immunization in the Americas are prepared from 
seeds derived from Edmonston B (EPI Newsletter, 1980). 
Several viruses like vesicular stomatitis virus (VSV) (Stojdl et al., 2000), 
Newcastle Disease virus (NDV) (Lorence et al., 1988), human reovirus (Coffey 
et al., 1998), recombinant adenovirus (Toth et al., 2010), recombinant Herpes 
simplex virus (HSV) (Yoon et al., 2000), recombinant vaccinia virus (VACV), 
recombinant measles virus (MeV) and some more viruses have already been 
tested positive with regard to their oncolytic potential. 
Now that virotherapeutics have entered clinical trials, it has to be investigated 
which viral vector is the most suitable oncolytic agent in which kind of cancer. 
The ultimate goal would be to treat cancer patients in the future with 
“customized” virotherapeutics, which specifically address patient individual 
tumor biologies. This can be achieved due to the fact that virotherapeutics are 
of recombinant nature thus allowing a straightforward encoding of “customized” 
functional transgenes on each and every vector modification.  
INTRODUCTION 
 5 
1.3 Vaccinia vaccine viruses GLV-1h68 and GLV-1h95 
In the 18th century Edward Jenner carried out the first vaccinations in humans 
using a cowpox virus called ‘vaccinia’ in England. In 1958, the World Health 
Organisation started a vaccination campaign with VACV to eradicate smallpox 
(variola) worldwide. In 1979, smallpox was declared eradicated throughout the 
globe (Fenner, 1993). A molecular biological investigation revealed that the 
used VACV was not identical with the virus Jenner had used. Researchers 
suspect that the vaccinia virus, which was held for a cowpox virus, is in fact an 
already extinct animal pox virus. So the origin of this specific virus remains 
unclear. 
Variola and VACV belong to the genus Orthopoxvirinae in the biological family 
Chordopoxvirinae. The poxvirus is the largest known virus and the particles can 
reach a diameter of 100-300 nm and have a clearly structured surface.  
 
Figure 2. Schematic representation of VACV 
The intracellular form of a VACV particle is shown (IMV = intracellular mature virus). The 
extracellular form is surrounded by a lipoprotein envelope containing several viral surface 
Surface proteins 
Lateral bodies 
Core 
dsDN
A 
Outer membrane 
Inner membrane 
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proteins. The dsDNA is associated with different viral enzymes and regulatory proteins which 
stabilize the supercoiled structure of the s-shaped dsDNA. The biconcave core consists of viral 
proteins and surrounds the dsDNA. Both lateral bodies lie next to the concavity of the core, their 
function is unknown. 
 
 
Figure 3. Replication cycle of VACV 
VACV enters the cell via membrane fusion. The virion is released into the cytoplasm. VACV 
replicates in the cytoplasm and does not enter the nucleus. Early genes are expressed first, 
leading to the formation of the early enzymes. These enzymes lead to the next steps e.g. 
secretion of several proteins, uncoating of the virion, synthesis of DNA polymerases and to the 
activation of transcriptional transactivators of the intermediate class of genes. DNA replication 
lasts about 2-12 hours. Intermediate mRNAs encode late transactivators which activate the 
transcription of late mRNAs resulting in the expression of late enzymes, early transcription 
factors and structural proteins. Virus assembly of new virions takes another 4-20 hours until the 
mature virion exits the cell via the cell membrane (Moss et al., 1998). 
 
As already described in the previous paragraph, there is a wide range of 
potential oncolytic agents. So why is VACV such a suitable oncolytic agent? 
One reason is related to its short and well-characterized life cycle. First, viral 
particles are released 8 hours post infection (hpi) and infected cells disintegrate 
already at 48 to 72 hpi according to data being provided in this dissertation and 
published data (Kirn et al. 2009). Furthermore, VACV is able to infect and lyse a 
large amount of different tumor tissues because of its ability to enter tumor cells 
without the use of a distinct receptor but by membrane fusion (Moss, 2006). It 
replicates within the cytoplasm without penetrating into the nucleus and 
integrating into the host genome. A further safety aspect is the lack of airborne 
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spread of vaccinia species. The VACV genome is genetically very stable and 
provides a large insertion capacity (of up to 25 kb) for transgenes (Chen et al., 
2009). It does not cause any known disease in humans (Roizman et al., 1994) 
and because of its use as smallpox vaccine, viral side effects are well-
documented and there is the chance to react to them with vaccinia specific 
therapeutics (Cono et al., 2003). Because of its enveloped forms containing 
complement control factors of the host’s immune system (EEV = extracellular 
enveloped virion), VACV is able to escape the immune system and spread 
through the host’s bloodstream (Vanderplasschen et al., 1998). Therefore, the 
fight against distant metastases has become a realizable aim of virotherapy 
after systemic or intratumoral administration of VACV. 
 
The virus used in this dissertation is VACV-based virotherapeutic vector GLV-
1h68. GLV-1h68 was derived from the LIVP strain (Lister strain from the 
Institute for Research on Viral Preparations, Moscow, Russia) which itself 
originated from the Lister strain (Al'tshteĭn et al., 1985). The construction of the 
GLV-1h68 virus has been described in detail before (Zhang et al., 2007). The 
GLV-1h68 genome includes four expression cassettes encoding the Renilla 
luciferase-Aequorea green fluorescent protein (ruc-gfp) in the F14.5L locus, a 
reverse inserted human transferrin receptor (rtfr), β-galactosidase (lacZ) in the 
J2R (thymidine kinase) locus and β-glucuronidase (gusA) in the A56R 
(hemagglutinin/ HA) locus of the viral genome. 
 
Figure 4. Genome of the GLV-1h68 virus derived from LIVP (Zhang et al., 2007) 
GLV-1h68 is a genetically stable, replication competent, recombinant, attenuated (Buller et al., 
1985) VACV that selectively infects cancer cells and was tested harmless to healthy tissues and 
organs (Zhang et al., 2007). The contribution of inactivated F14.5L to the attenuation of GLV-
1h68 was examined by comparing the virulence of GLV-1h68 with F14.5L-null and revertant 
viruses Zhang et al., 2009). The attenuation of GLV-1h68 was confirmed in several tumor 
models and was lately shown in a clinical study in the Royal Marsden Hospital (data not 
published yet). 
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Figure 5. Genome of the GLV-1h95 variant derived from GLV-1h68 
VACV GLV-1h95 is based on the GLV-1h68 virus containing the additional transgene FCU1 
(yeast FCY1/FUR1 fusion gene) (Erbs et al., 2000) in the A56R locus. For inserting FCU1, gusA 
had to be taken out of A56R. The FCU1 parental plasmid was provided by Transgene. The 
transgene was amplified by Jochen Stritzker (Würzburg) and inserted downstream of a VACV 
synthetic late promoter PSL. FUC1 encodes the enzymes Cytosine Deaminase (FCY1) and 
uracil phosphoribosyltransferase (FUR1) which convert the prodrug 5-fluorocytosine into the 
chemotherapeutic 5-fluorouracil. So GLV-1h95 was armed with a suicide gene to enhance the 
cytotoxicity in comparison to the non-armed GLV-1h68. 
 
1.4 Measles virus MeV-SCD 
 
 
Figure 6. Measles virus (MeV) including six structural proteins and the negative strand 
RNA (Guy Ungerechts, NCT Heidelberg) 
 
MeV belongs to the family Paramyxoviridae genus Morbillivirus. Wild type MeV 
is an enveloped virus with a nucleocapsid core. The negative strand RNA 
genome encodes six structural proteins N (nucleocapsid protein), P 
(phosphoprotein associated with RNP in polymerase complex), M (matrix 
protein), F (fusion glycoprotein), H (haemagglutinin) and L (large protein). The 
expression of the six structural proteins follows a transcriptional gradient which 
means that the most upstream gene (N) is transcribed most abundantly. The 
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negative strand RNA serves as a template for the positive antigenome strand, 
which vice versa serves as a template for further negative strand RNA. 
Paramyxoviridae replicate within the cytoplasm. The H-protein located on the 
viral surface binds to the cellular receptor. The F-protein is the second surface 
protein on the viral lipid envelope. It is required for the fusion of the viral and the 
cellular membrane. The P-, N- and L-protein initiate replication whereas the M-
protein serves as a structural protein within the virus. 
Replication starts with the transcription of viral RNA into mRNA by RdRP (RNA-
dependent RNA polymerase, consisting of P- and L-protein) from the 3’ end to 
the 5’ end of the genome. Due to the genome structure (Figure 7), the RdRP 
complex has to reinitiate transcription at each gene start signal encoding for a 
structural protein. As RdRP may drop off the template, the above-mentioned 
gradient in mRNA synthesis arises. Having translated enough N-protein, the 
RdRP starts to generate full-length antigenomic transcripts, which then serve as 
templates for the production of genomic RNAs. Both genomes and antigenomes 
can be packaged into virions. The lipid bilayer envelope around the new virions 
is derived from the host cell membrane. 
In 1954, a MeV was isolated from the eleven-year old David Edmonston and 
was attenuated in several passages in cell culture (Griffin et al., 1996). This so-
called attenuated Edmonston-B-strain was used for measles vaccination by the 
WHO as described previously. 
For infection trials in cell culture a vector derived from the Edmonston-B-strain 
called MeV-GFP was used carrying the marker gene GFP in the leader position. 
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MeV-GFP 
    MeV-SCD 
 
Figure 7. Wild type MeV genome (light blue) and MeV-SCD/GFP genome (orange) 
Wild type MeV genome (light blue) consists of six regions coding for structural proteins N 
(nucleocapsid protein), P (phosphoprotein), M (matrix protein), F (fusion glycoprotein), H 
(haemagglutinin) and L (large protein). SCD (dark blue) was inserted into the leader position of 
the attenuated Edmonston-B-strain. The arrow sizes correspond to the size of the respective 
genes. 
 
To enhance the oncolytic potential MeV was armed by inserting the SCD gene. 
SCD encodes a fusion protein consisting of yeast cytosine deaminase and 
yeast uracil phosphoribosyltransferase (see below). The SCD gene was 
positioned in the leader position to ensure sufficient production of SCD-enzyme 
(gradient). The insertion of SCD into the leader position did not result in an 
inhibition of viral replication. The vector sequence of MeV-SCD is 100% 
identical to the vaccine strain Schwarz (Mérieux) and was cloned by Sascha 
Bossow (NCT Heidelberg). 
 
1.5 Suicide gene therapy enhances viral oncolytic efficiency 
To enhance the cytotoxicity of MeV and VACV on tumor cells, both viruses were 
armed with the suicide gene Super Cytosine Deaminase (SCD). 
The Cytosine Deaminase (CD)/ 5-fluorocytosine (5-FC) suicide gene system 
was introduced in 1982 (Nishiyama et al., 1982). The enzyme CD catalyzes the 
deamination of cytosine to uracil in fungi (Erbs et al., 1997) and bacteria (de 
Haan et al., 1972), but is not existent in mammalian cells. Furthermore CD is 
able to convert 5-fluorocytosine to 5-fluorouracil. 5-FC is a common antifungal 
(Tassel et al., 1968) drug but was tested harmless to healthy mammalian cells 
(Akbulut et al., 2003). Despite the successful usage of the Escherichia coli CD 
(Kuriyama et al., 1999), the yeast CD extracted of Saccharomyces cerevisiae 
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species was considered more effective than the typically used bacterial CD 
(Hamstra et al., 1999). Moreover it is hypothesized that the combination of the 
YUPRT and the YCD enhances tumor cell sensitivity to 5-FU. So, Graepler et 
al. again generated the bifunctional Super Cytosine Deaminase (SCD) fusion 
gene consisting of YUPRT, which converts 5-FU into 5-FUMP, and YCD 
(Akbulut et al., 2003). Hence, a MeV vector carrying the SCD gene in the leader 
position was cloned by Neubert et al., MPI of Biochemistry, Martinsried. First 
investigations confirming the functionality and the oncolytic success in vitro of 
this engineered MeV-SCD and first in vivo studies were completed recently 
(Lampe et al., manuscript submitted). 
In case of VACV, GLV-1h95 was derived from GLV-1h68 by replacing the gusA 
gene by the yeast FCU1 (FCY1/FUR1) fusion gene. The FCU1-gene also 
combines the enzymatic activities of the FCY1- (Saccharomyces cerevisiae 
cytosine deaminase) and the FUR1-gene products (uracil 
phosphoribosyltransferase) and was established because the suicide gene 
therapy with the FCY1-gene and the FUR1-gene alone or in combination was 
ineffective in vitro (Fogar et al., 2007).  
 
Figure 8. Yeast FCY1/FUR1 (FCU1) fusion gene (Erbs et al., 2000) 
 
The great advantage of the Super-CD/ 5-FC system was that the systemically 
administered prodrug 5-FC showed no cytotoxic side effects outside the tumor 
tissue. The tumor cells were transfected with SCD using MeV-SCD or VACV as 
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a vehicle. So, SCD was only expressed in tumor cells and not in non-
transformed mammalian cells, which led to selective conversion of the non-toxic 
prodrug 5-FC into the highly cytotoxic compound 5-FU within the tumor. 5-FC 
can be applied systemically. As 5-FU is a highly diffusible molecule (Kuriyama 
et al., 1998), it provides an effective bystander effect meaning that it also kills 
primarily non-infected neighbouring cells. 5-FU is a very common clinical 
chemotherapeutic for diverse tumor-entities (Hofer et al., 1998; Kuriyama et al., 
1999). 
The mechanism leading to cell death consists of two different pathways which 
can be seen in Figure 9. 5-FC first is deaminated into 5-FU by the CD. The 
YUPRT converts 5-FU into 5-FUMP. Both RNA and DNA synthesis can be 
inhibited by 5-FU in the following ways: When 5-FUMP is phosphorylated to 5-
FUDP and 5-FUTP, 5-FUTP is incorporated into RNA which leads to a stop of 
protein synthesis. 5-FUDP can also be reduced to 5-FdUDP and hydrolyzed to 
5-FdUMP which is a competitive inhibitor of thymidylate synthetase (TS), which 
catalyzes the indispensable conversion of dUMP to dTMP. dTMP is 
phosphorylated to the nucleotide dTTP, which is one of the four necessary 
components for the de novo synthesis of DNA. 5-FdUDP can also be 
phosphorylated to 5-FdUTP which is incorporated into DNA. 
 
 
Figure 9. Suicide gene therapy using the Super-CD/ 5-FC system 
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5-FC is converted into 5-FU by Cytosine Deaminase (CD). One part of the 5-FU is renally 
excreted as FBAL. UDP converts 5-FU to 5-F-uridine which is transformed into the key 
metabolite 5-FUMP. 5-FUMP is incorporated into RNA after its phosphorylation to 5-FUTP. 5-
FUMP can also be reduced to 5-FdUMP which inhibits TS. The inhibition of dTMP synthesis 
stops the incorporation of dTTP (activated dTMP) into the DNA resulting in an inhibition of DNA 
synthesis. 5-FC–5-fluorocytosine, 5-FU-5-fluoruracil, FBAL- α-fluoro-β-alanin, 5-F-uridine-5-
fluorouridine, 5-FUMP- 5-fluorouridine monophosphate, 5-FUTP-5-fluorouridine triphosphate, 5-
FdUMP-5-fluorodeoxyuridine monophosphate, CD-cytosine deaminase, UDP-uridine 
phosphorylase, DPD-dihydropyrimidine dehydrogenase, UDK-uridine kinase, TS-thymidylate 
synthetase. (Chung-Faye et al.) 
 
1.6 Aim of this dissertation 
The treatment of solid tumors being resistant to first line therapies like surgery, 
chemotherapy and radiation displays a huge problem in today´s cancer therapy. 
Therefore, alternative therapy options are shortlisted for additional treatment of 
cancer. One of these alternative treatment options is the use of therapeutic 
oncolytic viruses called virotherapy. For each cancer species the most 
“appropriate” and promising viral vector must be found, especially for first line 
therapy resistant tumors.  
This dissertation was destined to characterize two genetically engineered, 
attenuated, replication competent viral vector systems, VACV and MeV, with 
regard to their basic infection efficacy, their replication behaviour within tumor 
cells and their oncolytic potential in vitro. The antitumor efficacy of both 
virotherapeutic systems should be investigated in a non-armed (2nd generation) 
and in an armed (3rd generation) version of each of the tow vector systems. The 
armed vectors express the suicide gene SCD which is able to toxify the non-
toxic prodrug 5-FC. 
First of all, we set out to investigate if there is a difference in the oncolytic 
potency between the MeV system and the VACV system. Secondly, our 
experiments should make clear if there are differences in the oncolytic potential 
between the armed and non-armed versions of the respective vectors. 
Moreover, it then was needed to demonstrate that virotherapy using these 
potentially oncolytic agents does not harm healthy tissue in the tumor 
environment but indeed selectively kills the tumor cells. 
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2 Materials and methods 
2.1 Cell culture 
2.1.1 Cell culture materials 
Cell culture materials  
DMEM with stable L-glutamine with 
4.5 g/l glucose 
Biochrom AG 
 
OPTI-MEM® Gibco/ Invitrogen 
RPMI PAA Laboratories GmbH 
William´s E + GlutaMAXTM –I Gibco/ Invitrogen 
Fetal bovine serum (FBS) PAA Laboratories GmbH 
HEPES buffer, 1M in 0.85% NaCl Lonza, AppliChem GmbH 
phosphate buffered saline (PBS) 
without Ca2+ and Mg2+ 
Trypsin/ EDTA 0.05% 
PAA Laboratories GmbH 
 
PAA Laboratories GmbH 
L-glutamine Biochrom AG 
NEAA (non essential amino acids) 
D-(+)-glucose 45% 
4% paraformaldehyde (PFA)  
PAA Laboratories GmbH 
Sigma 
Otto Fischar GmbH 
Penicillin Streptomycin Bio Whittaker®, Lonza 
Gentamycin CAMBREX 
Trypan Blue solution 0.4% 
Triton-X-100 
Sigma 
Roth 
ddH2O MilliQ Synthesis System 
       
All media, antibiotics, PBS, Trypsin/EDTA 0.05%, L-glutamine and D-(+)-
glucose were stored at 4°C during the time of use. Trypsin/EDTA 0.05% and 
FBS were stored at -20°C before use. The FBS was heat-inactivated at 56°C for 
30 minutes. 
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2.1.2 Characteristics of the cell lines 
Name Origin Species Culture medium Morphology 
Tumor cell lines 
A673 
 
extraosseus 
Ewing´s sarcoma 
human DMEM-10 
 
BRZ 
alveolar 
rhabdomyosarco
ma 
human DMEM-10 
 
SRH 
sclerosing 
rhabdomyosarco
ma 
resistant to first 
line 
chemotherapy 
human, 
primary 
DMEM-10 
 
 
 
SCOS 
osteosarcoma 
resistant to first 
line 
chemotherapy 
human, 
primary 
DMEM-10 
 
 
PLC/PRF/5 
 
hepatoma 
 
human 
 
DMEM-10 
 
 
CC531s 
 
colorectal 
adenocarcinoma 
rat 
 
DMEM-10 
supplemented with 
1 mM HEPES 
buffer 
 
MATERIALS AND METHODS 
16 
 
SKOV3ip.1 
 
ovarian 
adenocarcinoma 
murine DMEM-10 
 
 
HT-29 
 
colorectal 
carcinoma 
human DMEM-10 
 
 
SiHa 
 
cervical 
squamous cell 
carcinoma 
human 
 
DMEM-10 
containing 1% 
NEAA  
 
NCI-H1299 
 
breast 
adenocarcinoma 
human 
 
DMEM-10 
containing 10 mM 
HEPES  
Non-tumor cell lines 
PHH 
primary human 
hepatocytes 
human 
500 ml DMEM 
supplemented with  
21 µl insulin (10 U), 
188 µl 
hydrocortisone and 
5 ml 
penicillin/streptomy
cin (100.000 U/ ml)  
 
Vero 
African green 
monkey kidney 
epithelial cells 
simian DMEM-10 
 
CV-1 
African green 
monkey kidney 
fibroblasts 
simian DMEM-10 
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2.1.3 Cell culture 
The cell lines described in the previous paragraph were cultivated as permanent 
cell cultures and were maintained as adherent monolayer. All cell lines except 
the PHHs were grown in Dulbecco’s modified Eagle medium (DMEM) 
containing 10% heat-inactivated fetal bovine serum (FBS) (DMEM-10) at 37°C 
in a humidified atmosphere of 5% CO2 in plastic culture flasks. No antibiotic or 
fungicide was added in the media except in the medium of primary human 
tissue which was supplemented with penicillin/ streptomycin. All cultures were 
tested to be free of mycoplasma. 
When cells grew confluent, they were passaged every two to three days to 
avoid a lack of nutrients. All media and buffers were warmed to 37°C before 
use. 
 
To passage the confluent cell lines, they were washed once with PBS to 
eliminate dead cells and the rest of the FBS in the culture flask. Afterwards, 
trypsin/ EDTA 0.05% was added. To optimize the activity of the protease 
trypsin, the culture flask was placed into the incubator at 37°C for two to eight 
minutes. The supplemented EDTA exerted an additional effect: it acidulated the 
cell solution and led to a maximum effect of the trypsin. Under the treatment 
with trypsin/ EDTA 0.05%, cells detached from the plastic ground of the culture 
flask. Fresh culture medium was added to stop the activity of the trypsin. Cells 
were centrifuged in a 50 ml Falcon tube at 1200 rpm for five minutes at room 
temperature (RT) and the cell pellet was resuspended in fresh medium. One 
fifth to one tenth of the cell solution was cultivated in fresh medium again. The 
split ratios of the different cell lines were empirically determined. 
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Kind of vessel Growth area 
[cm2] 
Media volume 
[ml] 
Trypsin/EDTA 
[ml] 
Multi-well plate    
96-well 0.32-0.6 0.2 - 
48-well 1 0.4 - 
24-well 2 0.5 - 
6-well 9.5 2 0.5 
Petri-dish    
60x15mm - 9 - 
Culture flask    
750 ml 175 25 5 
300 ml 75 15 2.5 
Table 1. Growth area and volumes used in various culture vessels 
 
2.1.4 Cryopreservation of cells 
To create a standby of cells, cells were expanded in 75 cm2 culture flasks and 
were frozen at -180°C in cryovials. Therefore, cells which were in the 
exponential growth stage were trypsinized and centrifuged as described in 
3.1.3. The cell pellet was resuspended in DMEM containing 10% 
dimethylsulfoxide (DMSO) and 20% FBS. Aliquots of 1 ml volume each were 
immediately frozen at -80°C and transferred to -180°C for long time storage one 
day later. 
 
2.1.5 Thawing of cells for recultivation 
One aliquot of the respective cell line was quickly thawed in the water bath at 
37°C. Cells were immediately added to 9 ml prewarmed culture medium and 
centrifuged at 1200 rpm for five minutes at RT. The cell pellet was resuspended 
in 10 ml fresh culture medium and transferred into a culture flask. 
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2.1.6 Cell count determination with the Neubauer haemocytometer 
 
Figure 10. Neubauer haemocytometer 
 
Before seeding cells, exact cell count was determined. Cells were trypsinized 
and centrifuged as described in 3.1.3. Cells were resuspended in DMEM-10 
and 10 µl of the cell suspension were added to 90 µl trypan blue (0.4% w/v, 
Sigma). Trypan blue served to differentiate between dead and healthy cells. 10 
µl cell suspension were pipetted into the chamber between the hemocytometer 
and a glass cover. Healthy cells appeared white under the microscope in front 
of the blue background. Cells in the four quadrants of the Neubauer 
hemocytometer were counted and the mean was calculated. The mean was 
multiplied with 104 because each quadrant measures 10-4 cm2 and the result 
was multiplied with the factor 10 because of the 1:10 dilution in trypan blue. 
 
              
510×=
quadrants
cellscounted
ml
cells
 
 
2.2 Virus infection 
2.2.1 Virus infection without suicide-gene therapy 
One day before infection, cells were seeded out in culture medium in cell culture 
plates or in petri dishes. The next day, virus stock was diluted to the necessary 
titer in OPTI-MEM®. Infection took place in OPTI-MEM®, using different 
multiplicities of infection (MOI). MOI means the number of infectious virus 
particles per cell at the time point of infection. After the infection the plates were 
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placed into the incubator at 37°C. Plates were gently moved every 15 minutes 
to facilitate equal infection. 3 hpi (MeV)/ 1 hpi (VACV), the inoculum was 
aspirated and replaced by fresh culture medium. 
For the production of growth curves of GLV-1h68 in CC531s- and SKOV3ip.1-
cells, virus stock solution was diluted in DMEM supplemented with 2% FBS 
(DMEM-2) and cells were infected as described previously. 
 
Plate/ dish Culture medium/ well Inoculum/ well 
6-well plate 2 ml 1 ml 
24-well plate 500 µl 250 µl 
60x15mm petri dish 9 ml 4 ml 
Table 2. Volumes used for culture medium and inoculum in different cell cultures  
 
2.2.2 Virus infection combined with suicide-gene therapy and 5-FC 
As MeV-SCD and GLV-1h95 express the suicide genes SCD and FCU1, the 
inoculum was replaced by fresh culture medium supplemented with different 
concentrations of the prodrug 5-fluorocytosine (5-FC). 5-FC is normally used as 
an antifungal nucleoside analogue in clinical approach as it showed antifungal 
effects and provided no toxic effect to humans. The SCD/ FCU1 gene products 
expressed in infected cells convert 5-FC into the highly diffusible toxic 
metabolite 5-fluorouracil (5-FU), which leads to RNA miscoding followed by 
incorrect protein synthesis and inhibits DNA synthesis. 5-FU is a common 
chemotherapeutic in clinical use. 5-FC was used at 1 mM, 10-1 mM, 10-2, 10-3 
and 10-4 mM. 3 hpi (MeV-eGFP) or 1 hpi (GLV-1h95), the inoculum was 
removed and the cells were treated with the before prepared 5-FC solutions in 
quadruplicates ab initio (Figure 11). To lengthen the process of viral replication, 
5-FC was alternatively added 48 hpi because the toxic metabolite 5-FU is likely 
to inhibit viral replication as well as the host DNA replication (McCart et al., 
2000). 
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Figure 11. 5-FC concentrations in a 24-well plate 
5-FC was added to the 24-well plate in increasing concentration steps from 0.0001 mM to 1 mM 
in quadruplicates. Four wells were treated with 0 mM 5-FC and DMEM-10 solely. Same colour 
means same 5-FC-concentration. 
 
2.3 Overview of cell-virus interaction in electron microscopy 
To visualize the behaviour of GLV-1h68 in the infected cell lines CC531s and 
SKOV3ip.1 and the behaviour of MeV-SCD in the infected cell lines A673 and 
BRZ, electron microscopy was performed with the help of B. Fehrenbacher, 
Dermatology, University Hospital Tübingen. 
2x106 cells were seeded out per 10 cm petri dish in 9 ml DMEM-10. The next 
day, one dish of each cell line remained mock infected and three dishes were 
infected with GLV-1h68 at the MOI of 0.1 and with MeV-SCD at the MOI of 1 as 
described in 3.3.1. 
24, 48, 72 and 96 hpi the cells from one petri dish of each cell line were 
trypsinized and centrifuged as described before. The cell pellet was fixed in 500 
µl Karnovsky fixing solution for one hour at RT and subsequently stored at 4 °C. 
The Karnovsky fixing solution is composed of two separate solutions. Solution A 
consists of 30 ml 0.2 M natrium-cacodylate, 40 ml 7.5% paraformaldehyde and 
50 mg CaCl2 dissolved in triple distilled H2O. Solution B consists of 30 ml 12% 
glutaraldehyde dissolved in triple distilled H2O. Both solutions were frozen in 
separate cryovials. The solutions should be defrosted and mixed immediately 
before use. 
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The mock-infected cells were fixed 48 hpi because of high confluence at this 
time point. Electron microscopy was done by B. Fehrenbacher, Dermatology, 
University Hospital Tübingen. 
 
2.4 Detection of GFP by fluorescence microscopy 
Cells were infected as described before. Fluorescence microscopy was done at 
different time points post infection using the OLYMPUS IX50 microscope and 
the associated OLYMPUS U-RFL-T function for the fluorescence photos, which 
were taken with the F-View Soft Imaging System and the corresponding 
anaLYSIS software. 
Phase contrast photos were taken at 4x lens magnification using the PhL ocular 
or at 10x lens magnification using the Ph1/ PhC ocular. Fluorescence photos 
were taken of the same detail as the phase contrast photos using the 
fluorescence light filter. Phase contrast and fluorescence photos were finally 
overlaid. 
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2.5 Quantification of the relative fluorescence intensity 
5x104 cells per well were seeded in one half of a 24-well plate, which is 
exemplarily shown in Figure 12. On the following day, cells were either mock-
infected or infected with GLV-1h68 at MOI 0.1 and 1 in quadruplicates. The 
inoculum was replaced by DMEM-10 1 hpi. Fluorescence intensity was 
measured 24, 48, 72 and 96 hpi using the Multiplate Elisa Reader Tecan 
GENios Plus and the software XFluor4. Fluorescence intensity was measured 
in random circle points in each well. 
 
Figure 12. Green fluorescence intensity measurement 
The upper half of the 24-well plate was used for green fluorescence measurement in the Tecan 
GENios Multiplate Elisa Reader. Four wells (same colour) formed a group of mock-infected cells 
or cells infected at MOI 0.1 and 1. The detail on the right shows the random circle points of 
green fluorescence measurement in one well. 
 
2.6 β-galactosidase detection by lacZ-staining 
2.6.1 Materials for lacZ-staining 
X-Gal staining was first performed using `The Senescence Cells Histochemical 
Staining Kit´ from Sigma. The staining kit was replaced by an alternative X-gal 
staining method. 
 
Senescence Cells Histochemical Staining Kit (Sigma-Aldrich) 
Contents of the staining kit: 
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X-Gal solution, staining solution, reagent B, reagent C, PBS 10x, fixation 
solution 10x 
 
Alternative X-Gal staining method  
PBS 1x PAA Laboratories GmbH 
Paraformaldehyde (PFA) 4.0% Otto Fischar GmbH 
Glutaraldehyde 25% Roth 
K2[Fe(CN6)]  Sigma 
K3[Fe(CN6)] Sigma 
MgCl2 1M (1.017g MgCl2 in 5 ml ddH2O) - 
X-Gal  Carl Roth GmbH 
 
2.6.2 Experimental procedure of lacZ-staining 
The lacZ staining assay is an established method to show the presence of β–
galactosidase, an enzyme which is encoded by the lacZ-gene within the GLV-
1h68 genome. 
The intracellular β-galactosidase activity can be detected by the colour change 
of the colourless substrate X-Gal (5-brom-4-chlor-3-indoxyl-β-D-
galactopyranosid) into blue (indigoid dye: 5,5'-dibrom-4,4'-dichlor-indigo) after 
getting converted by the β-galactosidase enzyme. Our purpose was to reveal 
the ability of GLV-1h68 to infect the analyzed cell lines. As it has already been 
tested successfully, we used the Senescence Cells Histochemical Staining Kit 
from Sigma for this assay but changed to a low priced variant of self-preparing 
the required contents. 
 
1x106 cells were seeded out in 500µl DMEM-10 per well onto a 24-well plate 
and were infected with GLV-1h68 in quadruplicates at the MOI of 0.1 and 1 or 
remained mock-infected 24 hours later. 
At the time point of interest, the cells were washed twice with 500 µl 1x PBS per 
well. The fixation solution was prepared by combining 4.92 ml PBS 1x, 0.08 ml 
25% glutaraldehyde and 5 ml 4% paraformaldehyde. Afterwards, cells were 
fixed using 700 µl of the fixation solution per well for a minimum of six minutes 
at RT. The staining solution consisted of PBS, K2[Fe(CN6)]-solution, 
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K3[Fe(CN6)]-solution, MgCl2 and X-Gal, which was heated up to 37°C to avoid 
precipitation. The staining solution was filtered through a 0.2 µm filter to 
eliminate potential aggregates which would disturb the staining result. The exact 
assembly of the fixing and the staining solution is reported in Table 3. 10 ml of 
each the fixing and the staining solution were prepared. 
 
 
 
Content Concentration 
 
Fixing solution 
PBS 1x 
PFA 4% in PBS 
glutaraldehyde 25% 
 
Staining solution 
PBS 1x 
K2[Fe(CN6)] 50 mM in DMSO 
K3[Fe(CN6)] 50 mM in PBS 
MgCl2 1 M in ddH2O 
X-Gal 400 mg in 10 ml DMSO 
Table 3. Fixation and staining solution for β-galactosidase-staining using X-Gal 
 
For 10 ml fixing solution 4.92 ml PBS, 5 ml PFA and 0.08 ml glutaraldehyde 
were used, for 10 ml staining solution 7.73 ml PBS, 1 ml K2[Fe(CN6)], 1 ml 
K3[Fe(CN6)], 0.02 ml MgCl2 and 0.25 ml X-Gal were pipetted together. 
Subsequently cells were washed three times with PBS again before staining the 
cells with 750 µl of the staining solution per well. Plates were sealed with 
parafilm and stored at 37°C in a CO2-free atmosphere. After at least two hours 
infected cells appeared blue visible to the naked eye and by using the brightfield 
microscopy. Photos were taken using the OLYMPUS IX50 microscope, the F-
View Soft Imaging System and the analySIS program. 
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2.7 Western Blot analysis 
2.7.1  Materials for Western Blot analysis 
Tris-buffered saline (TBS) (pH 7.4) 
 
NaCl 150 mM 
Tris 50 mM 
adjust pH with HCl (37%) 
Tris-buffered saline-Tween TBS (pH 7.4) 
0.02% Tween-20 
Tris-buffered saline-Triton (TBS-T) TBS (pH 7.4) 
0.02% Triton-100 
1x Wet-Transfer-buffer Tris 48 mM 
Glycine 39 mM 
MeOH 20% 
PAGE 5x Running-buffer (pH 8.3) 125 mM Tris 
950 mM glycine 
0.5% w/v SDS 
adjust pH with HCl (37%) 
Tris-HCl (pH 8.8) 1.5 M, adjust pH with HCl (37%) 
Tris-HCl (pH 6.8) 1 M, adjust pH with HCl (37%) 
Sodiumdodecyl-sulfate (SDS) 10% w/v ddH2O 
ammonium persulfate (APS) 10% w/v in ddH2O 
TEMED C6H12N2 - 
Table 4. Chemicals for Western Blot analysis 
 
Primary antibodies 
Target structure Species/ name  Dilution in Roti-Block Firm/ origin 
Vinculin (human) 
SCD 
Mouse/ V9131 
- 
1:10.000 
1:1.000  
Sigma-Aldrich 
Transgene S.A. 
Table 5. Primary antibodies for Western Blot 
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Secondary antibodies 
Target structure Species/ name  Dilution in Roti-
Block 
Firm/ origin 
Rat IgG (SCD) 
 
HRP-labelled, goat 
anti-rat 
1:20.000 
 
Biorad 
 
Mouse IgG 
(Vinculin) 
HRP-labelled, goat 
anti-mouse 
1:30.000 Biorad 
Table 6. Secondary antibodies for Western Blot analysis 
 
2.7.2 Preparation of cell lysates 
2x106 cells were seeded out in 8 ml DMEM-10 per 10 cm diameter petri dish. 
The next day, cells were washed once with 8 ml PBS per petri dish and 
afterwards infected at MOI 0.1 in 4 ml OPTI-MEM® or mock infected as 
described in 3.3.1. 48 hpi cells were washed once with 8 ml PBS and were 
subsequently lysed in 500 µl NP40 lysis buffer (50 mM Tris-HCl (pH 7.6), 150 
mM NaCl, 1% NP40). Cells were scraped off the bottom of the petri dish and 
transferred into a 1.5 ml reaction tube. Three freeze-thaw-cycles followed. Cells 
were first shock-frozen in liquid nitrogen and subsequently thawed again in the 
heating block at 37°C. Afterwards, the samples were centrifuged at full speed at 
4°C for five minutes and supernatants were transferred to fresh reaction tubes. 
 
2.7.3 Bradford dye Assay 
The Bradford dye assay (Bradford 1976) is based on the equilibrium between 
two forms of Coomassie Brilliant Blue G-250 dye. Under strongly acid 
conditions, the dye is most stable as a doubly-protonated red form. Upon 
binding to protein (especially to basic and aromatic amino acids) it is most 
stable as an unprotonated form. This leads to a shift of the absorption peak 
from 465 to 595 nm and the G-250 dye appears blue. The higher the protein 
concentration the higher is the absorption at 595 nm. 
Bradford dye assay was performed to determine the content of protein in the 
cell lysates, which were prepared for Western blot analysis. The BIO-RAD 
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protein assay kit (Bio-Rad Laboratories GmbH) was used for protein content 
examinations. 
To generate a standard curve a stock solution of bovine serum albumin (BSA) 
(10 mg/ ml) was diluted to the final concentrations 0.5, 0.25, 0.1 and 0.05 mg/ 
ml in ddH2O. 
The Bradford dye reagent was diluted 1:5 in ddH2O and the cell lysates were 
diluted 1:50 and 1:100 in ddH2O. 
10 µl of each dilution and of the standards were transferred in duplicate to a 96 
well plate. ddH2O was used as a blank. 200 µl Bradford dye were added to each 
well. The optical density (OD) of all samples was measured in the Multiplate 
Elisa Reader using the magellan software. The OD of the BSA standard served 
to generate a standard curve which was used as a reference to calculate the 
protein content of the samples. 
 
2.7.4 Sodium-dodecylsulfate-polyacrylamide gel electrophoresis 
Proteins can be separated according to their molecular weight by the Sodium-
dodecylsulfate-(SDS) polyacrylamide gel electrophoresis (PAGE) (Laemmli et 
al., 1970). The addition of β-mercaptoethanol leads to the breakup of the 
disulphide bridges and to the unfolding of the proteins. The attachment of SDS 
to the exposed proteins afterwards leads to a net charge of the protein 
according to its mass. 
First of all the buffer tank, the gel chamber, the stacking and the separating gel 
for the SDS-PAGE were prepared. The composition of the two gels is shown in 
Table 7. The polyacrylamide concentration of the separating and the stacking 
gel defined the pore size of the gels.  
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Content Separating gel (12%) Stacking gel (5%) 
ddH2O 3.3 ml 1.4 ml 
30% acrylamide 4.0 ml 0.33 ml 
1.5 M Tris (pH 8.8) 2.5 ml - 
1 M Tris (pH 6.8) - 0.25 ml 
10% SDS 0.1 ml 0.02 ml 
10% APS 0.1 ml 0.02 ml 
TEMED 0.004 ml 0.002 ml 
Table 7. Composition of the stacking and the separating gel 
 
ddH2O, 30% acrylamide, Tris and 10% SDS were mixed in a 15 ml tube. APS 
and TEMED were added to the separating gel, APS served as a radical and 
TEMED was the initiator of the polymerisation reaction. They both started the 
polymerisation, so the separating gel had to be filled into the gel cassette 
immediately. The gel was overlaid with some isopropanol to create a flat 
surface on which the stacking gel could be filled. Polymerisation took about 30 
minutes. Then the isopropanol was removed from the polymerized gel and the 
surface of the gel was washed once with ddH2O. 
APS and TEMED were added to the stacking gel and the stacking gel was 
immediately filled over the separating gel. The comb (which formed 10 slots) 
was inserted straight afterwards. Polymerisation took about 15 minutes. 
Then the gel cassette was placed into the buffer tank which was afterwards 
filled to the rim with the buffer solution. The slot-forming comb was carefully 
removed and the integrity of the slots was checked. 
75 µg of cell lysate per lane were loaded onto the gel. Before loading, one fifth 
of the sample volume of 6 x SDS loading buffer was added and samples were 
boiled for 5 minutes at 95°C. A positive control and a molecular weight marker 
(Full range rainbow protein marker, Amersham Biosciences) were added in one 
slot in addition. The molecular weight marker helped to identify the band of 
protein we were searching for. 
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2.7.5 Western blotting 
After separation by SDS-PAGE proteins were electrophoretically transferred to 
a polyvinylidene difluoride- (PVDF) membrane (Amersham Hybond P, GE 
Healthcare). Western blot analysis was done to proof the expression of Super 
Cytosine Deaminase (SCD) in the before infected cell lines. The enzyme SCD 
served as the evidence of MeV-SCD infection. 
The PVDF-membrane was wetted with methanol and was afterwards 
embedded between gel, Whatman papers and sponges as shown in Figure 13. 
 
Figure 13. The correct order of the blotting membranes from back to front 
sponge - 2 Whatman paper - gel - PVDF membrane - 2 Whatman paper – sponge. All layers 
were fixed and placed into the wet transfer buffer for blotting. 
 
All layers in this exact arrangement were prepared in a box with 1x wet transfer 
buffer (3.8.1) and were clamped in a special device to keep the gel close to the 
PVDF-membrane. It was very important to avoid air bladders between the gel 
and the Amersham Hybond P membrane because they would inhibit transfer. 
To control successful blotting the membrane was stained for two minutes with 
Ponceau-S solution (0.1% w/v Ponceau-S in 5% acetic acid). The staining 
solution was removed and the membrane was washed with ddH2O until the 
removed solution was almost free of Ponceau-S dye. 
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2.7.6 Staining of the protein bands 
To avoid the non-specific binding of the antibody, the membrane was blocked 
with 5% milk powder in TBS-Tween. The membrane was washed twice in TBS/ 
Triton and subsequently cut in two parts at 70 kDa, separating the 116 kDa 
Vinculin band from the 35 kDa SCD band. The primary anti-SCD antibody was 
diluted in 1x Roti-Block and the “SCD-part” of the membrane was incubated in 
this solution, the primary anti-Vinculin antibody was diluted in 1x Roti-Block and 
the “Vinculin-part” of the membrane was incubated in this separate solution at 
4°C on the shaker overnight. 
Antibody solutions were removed the next day and stored at 4°C for reuse after 
the addition of 0.05% sodium-acid.  
Afterwards both membranes were washed three times with TBS/ Triton for five 
minutes. 
The secondary horseradish peroxidase (HRP) labelled goat anti-rat antibody 
(SCD) was diluted 1:20.000 in Roti-Block, the secondary HRP labelled goat 
anti-mouse antibody (Vinculin) was diluted 1:30.000 in Roti-Block. Incubation 
within the antibody-solutions occurred on the shaker for one hour at RT. 
Afterwards both membranes were washed three times with TBS/ Triton for ten 
minutes. 
Proteins were visualized by enhanced chemiluminescence (ECL). Equal 
amounts of both components of the detection reagent were mixed and the two 
parts of the membrane were incubated in 1 ml ECL solution for three minutes. 
Afterwards, both membranes were fixed in a plastic foil in a Dr. GOOS Suprema 
UNIVERSAL 100 photo cassette (Dr.GOOS Suprema GmbH). The membranes 
were exposed to the high performance chemiluminescence film Amersham 
Hyperfilm™ ECL (GE Healthcare Limited). 
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2.8 Cell mass quantification using Sulforhodamine-B assay 
2.8.1 Materials for Sulforhodamine-B (SRB) assay 
Materials for SRB assay  
Tecan GENios Microplate Elisa Reader MTX lab systems 
24-well microplate TPP 
96–well microplate Costar 
phosphate buffered saline (PBS)  PAA Laboratories GmbH 
Trichloroacetic acid (TCA, 10% w/v) Roth 
Sulforhodamine B Sigma 
SRB staining solution (0.4% w/v in 1% 
acetic acid) 
Sigma 
Acetic acid (1%) Merck (100%) 
Tris-base solution (TBS) (10 mM) Sigma 
Table 8. Materials for SRB assay 
 
2.8.2 Procedure of SRB assay 
The SRB-assay (Skehan et al., 1990) provides the ability to quantify the drug- 
or virus-induced cytotoxicity in adherent cell culture (reduction of cell mass) 
because the measured optical density (OD) is correlated directly positive to the 
remaining number of cells in the respective sample. For this reason the SRB 
assay is often indispensable in cancer research to determine the drug-caused 
cytotoxicity and proliferation stop (Skehan et al., 1990). 
The SRB-dye is an anionic protein dye which binds to basic amino acids in 
TCA-fixed cells. After solubilising the SRB-dye, remaining protein mass can be 
determined by measuring the OD. In comparison to the measured OD in wells 
containing mock-infected cells, the change in protein mass (and indirect cell 
count) can be examined. 
4x104 cells per well were seeded in 24-well plates in 500 µl DMEM-10. On the 
following day cells were infected with different MOIs as it was described before. 
At the respective time point cells were carefully washed twice with 500 µl ice 
cold PBS per well and were subsequently fixed with 250µl cold 10% 
trichloracetic acid (TCA). Plates were stored for 30 min at 4°C. 
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After fixation, cells were washed three times with tap water. Plates were dried at 
40°C overnight and could be stored limitless at RT. 
To stain cells, 250 µl of the SRB-staining-solution were added to each well for 
ten minutes. The staining solution was removed and the wells were washed four 
times with 1% acetic acid to remove the not cell bound dye. Plates were dried 
for a minimum of 3-6 hours or overnight and measurement took place within the 
next 48 hours. To make cell mass measurable, the cell-associated dye was 
solubilised in 1 ml 10 mM tris base solution per well. To assure complete 
solution, plates were shaken some times and the tris base solution incubated 
for 10 minutes. Measurement took place in the Microplate Elisa Reader in a 
transparent flat-bottomed 96-well plate. 80 µl of each sample were transferred 
to the 96-well plate in duplicate. The OD was measured at 550 nm wavelength. 
 
2.9 LDH-release assay 
2.9.1 Materials for LDH-release assay 
Materials for LDH-release assay  
Tecan genios Microplate Elisa Reader MTX lab systems 
LDH-P mono Kit Analyticon Biotechnologies AG 
Triton X-100 Roth 
PBS PAA Laboratories GmbH 
Table 9. Materials for LDH-release assay 
 
2.9.2 Procedure of the LDH-release assay 
Lactate dehydrogenase (LDH) is the enzyme which catalyzes the 
interconversion of pyruvate and lactate in glycolysis under hypoxic conditions 
while the important oxidation of NADH into NAD+ is simultaneous. 
++ +⎯⎯ →←++ NADlactateHNADHpyruvate LDH  
 
At the instance of cell death, LDH is released. By detecting the amount of LDH 
released into the culture medium, cell death can be quantified in vitro. 
Measurement was performed in the Multiplate Elisa Reader with the program 
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magellan. LDH catalyzes the oxidation of NADH to NAD+. The conversion 
between the two coenzymes NADH and NAD+ can be easily detected because 
of the different ultraviolet (UV) absorption spectra between the oxidized and the 
reduced form. While NAD+ has a peak in absorption at the wavelength of 259 
nm, NADH has a peak at 339 nm in addition to its peak at 259 nm (Figure 14). 
By measuring the decrease of molecules showing a peak at 339 nm, the 
program can draw a conclusion to the released amount of LDH and the 
dimension of cell death. 
 
 
 
 
 
Figure 14. The oxidation of NADH to NAD+ is catalyzed by the enzyme lactate 
dehydrogenase 
The diagram shows the wavelength of the maximum absorption of UV-light of NAD+ at 259 nm 
wavelength and of NADH at 259 nm as well and the second peak at 339 nm wavelength. 
 
4x104 cells per well were seeded in a 24-well plate. 24 hours later, the cells 
were infected with different MOIs as described in 3.3.1. 
LDH substrate was prepared according to the manufacturer´s protocol. To 
measure LDH activity, the supernatant of the cells was transferred into a 48-well 
plate. Cells were lysed with 500 µl - 1 ml PBS containing 0.1% Triton per well. 
To ensure complete lysis, cells were incubated at 37°C for ten minutes. 
Complete cell lysis was controlled under the phase contrast microscope. 
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10 µl of each supernatant sample and 10 µl - 20 µl of each lysis sample 
depending on the amount of LDH in the respective cell line were transferred to a 
flat bottomed 96-well plate in duplicate. Before the NADH-solution was added 
the program magellan and the Microplate Elisa Reader were prepared ready. 
Afterwards 200 µl solubilised NADH-solution were added to each well of the 96-
well plate using the multichannel pipette. The plate was placed instantly into the 
Multiplate Elisa Reader. Received data was checked the moment straight after 
measuring if the amount of LDH was too high, these samples had to be diluted 
in some more medium containing 5% FBS and had to be measured again. 
Results were represented in diagrams performed with the program 
GraphPadPrism4.0. 
 
To present the percentage of LDH-release, 0.1% Triton/ PBS was used as a 
100% LDH release control and result values were calculated with the Microsoft 
Excel program as follows: 
 
( )backgroundternalayercelllysed
backgroundterna
LDHLDHLDH
LDHLDH
releaseLDH
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=
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2.10 Establishing of a growth curve to pursue the replication 
behaviour of the respective virus 
2.10.1 Procedure of measles virus growth curve 
2.10.1.1 Materials for the establishment of a measles virus growth curve 
 
Materials for the establishment of a measles virus growth curve 
Dulbecco´s modified Eagle´s medium 
Fetal bovine serum (FBS) 
Biochrom AG 
PAA Laboratories GmbH 
PFA 4% Otto Fischar GmbH 
Goat anti-mouse Alexa 546 
Anti-MeV-NP 
Molecular Probes 
Clone 120, ECACC (No.95040312) 
TBS-Tween 0.02% Tween: Promega 
Table 10. Materials for the establishment of a measles virus growth curve 
2.10.1.2 Production of the virus infected samples 
1x105 cells per well were seeded in a 6-well plate in 2 ml DMEM-5. The next 
day cells were infected with MeV ld-SCD at the MOI of 0.03 in 1 ml OPTI-
MEM® per well. 3 hpi the infection medium was removed. Cells were washed 
three times with PBS and 1 ml DMEM-5 was added. At the time points 3, 24, 
48, 72 and 96 hpi the supernatant of one well was aspirated and assembled in 
one reaction tube, the remaining cell monolayer was scraped off in 1 ml OPTI-
MEM® using a cell scraper and assembled in a separate reaction tube. 
Samples were frozen immediately at -80°C. 
 
2.10.1.3 Titration and the 50% end point dilution assay (TCID50 = tissue 
culture infectious dose 50) 
After assembling and freezing the 96 hpi sample, all samples were unfrozen 
again, vortexed and centrifuged for two minutes at 3000 rpm to separate cells 
from virus particles. Supernatants were transferred to fresh reaction tubes 
without dissolving the pellet. The transferred samples were diluted in a seven 
times 1:10 dilution series in DMEM-5 using a 96-well plate. 
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Figure 15. Sample dilution for virus titration in DMEM-5  
Samples were diluted in a 96 well plate. 300 µl per sample were transferred to the first line of 
the plate. 270 µl DMEM-5 were added to the rest of the wells. 30 µl of each sample were diluted 
tenfold in 270 µl with the multichannel pipette, new pipette tips were used for each dilution step 
(Rabenau et al., 2005). 
 
Titrations were performed on Vero cells which were seeded out some hours 
before in 96-well plates in DMEM-5. 50 µl of each sample dilution was 
transferred fourfold to the Vero-cells. 
96 hours later, cells were washed once with 150 µl PBS per well and were 
subsequently fixed with 50 µl PBS containing 4% PFA per well for ten min at 
RT. 
Infected cells were detected with virus-specific immunofluorescence-staining. 
Before staining, cells were washed twice with 200 µl PBS per well and 
underwent a 30 min blocking step in TBS-Tween containing 1% FBS to diminish 
nonspecific staining. Cells were stained with anti-MeV-NP antibody (anti-MeV-
NP, diluted 1:1000 in TBS-Tween, 50 µl per well). After 30 min cells were 
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washed three times with TBS-Tween. Incubation with the secondary antibody 
(goat anti-mouse, Alexa 546, Molecular Probes, diluted 1:1000 in TBS-Tween) 
was performed for 30 min in the dark. Afterwards cells were washed three times 
with 200 µl TBS-Tween per well. For fluorescence microscope observation, 100 
µl PBS was added to each well. Infected wells were detected microscopically, 
whereas each well with at least one infected cell was declared infected. 
Viral titer determination was done using the TCID50-formula. Viral titers were 
calculated and presented as [PFU/ml]. The growth curve was finally done using 
GraphPadPrism4.0. 
 
Figure 16. TCID50-titration for viral growth curve of MeV ld-TRK 
Dilution of virus samples (100 - 10-7) were transferred fourfold to Vero-cells in a 96 well plate. 96 
hpi cells were fixed and stained with anti-MeV-NP-antibody. Infected cells appeared red (shown 
here as red, lavender and blue) and the amount of wells containing infected cells per dilution 
were quantified in fluorescence microscopy. TCID50/ml concentration was calculated with the 
formula by Kärber and Spearman (Figure 17). 
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Figure 17. TCID50-formula by Spearman (1908) and Kärber (1931) 
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2.10.2 Procedure of Vaccinia virus growth curve 
2.10.2.1 Materials for the establishment of a vaccinia virus growth curve 
 
Virus plaquing overlay medium (1.5% carboxymethylcellulose) 
500 ml glass bottle containing a stir bar 
Dulbecco´s modified Eagle´s medium 
 
Biochrom AG 
PEN/STREP/Amphotericin B BioWhittaker®, Lonza 
Fetal bovine serum (FBS) PAA Laboratories GmbH 
Carboxymethylcellulose sodium salt 
(CMC) 
Sigma Aldrich 
Table 11. Materials for the preparation of virus plaquing overlay medium CMC 
 
 
7.5 g CMC were added to the 500 ml glass bottle. The bottle was autoclaved 
with the stir bar inside. Afterwards 500 ml DMEM were added under the hood. 
The CMC on the bottom of the bottle was dislodged with a 10 ml pipette and the 
bottle was placed on the stirrer overnight until all of the CMC was completely 
dissolved. 
The next day 25 ml FBS (5%) and 5 ml antibiotic-antimycotic-solution (1%) were 
added and the overlay medium was placed on the stirrer for 15 minutes again. 
The overlay medium was stored at 4°C. Right before use, it was warmed to RT. 
 
Crystal violet stain  
500 ml glass bottle containing stir bar 
Crystal violet 
 
Fluka Chemie AG 
37% formaldehyde Roth 
Ethanol  Merck 
Table 12. Materials for crystal violet stain 
      
0.65 g crystal violet was added to the 500 ml glass bottle containing a stir bar. 
25 ml ethanol was added additionally and the solution was stirred for about one 
hour. Afterwards 150 ml of 37% formaldehyde was added and the bottle was 
filled to the 500 ml mark with ddH2O. The staining solution was stirred overnight 
and then stored at RT. 
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2.10.2.2 Extraction of the virus infected samples 
5x105 cells per well were seeded out in 2 ml DMEM-10 in one and a half 6-well 
plates (9 wells). The next day cell count was determined as described in 3.1.6 
using three wells. The quantity of virus needed for infection was calculated 
according to the cell number.  
GLV-1h68 was thawed from -80°C and sonicated for 30 seconds. Right 
afterwards the infection solution was prepared for one 6-well plate requiring 500 
µl DMEM-2 per well plus a reserve; 3.5 ml. GLV-1h68 was immediately placed 
on ice until freezing again at -80°C. 
Cells were infected as described in 3.3.1. One hour later, the inoculum was 
removed and the plate was carefully washed two times with 2 ml PBS per well. 
2 ml DMEM-10 were added thereafter and the plate was placed into the 
incubator at 37°C. 
The rest of the inoculum was frozen at -80°C for the titration of the inoculum. 
Virus harvest took place 1, 24, 48, 72 and 96 hpi. One well of the 6-well plate 
was used for one time point. Cells were detached with a sterile cell scraper in 2 
ml DMEM-10 and were filled into a fresh Eppendorf cup. Each sample was 
frozen immediately after harvesting in -80°C until virus titration. 
2.10.2.3 Titrations and Crystal violet staining 
One day before titration, 2x105 CV-1 cells per well were seeded out in a 24-well 
plate in 500 µl DMEM-10. Alternatively, 1x105 cells per well in 500 µl DMEM-10 
were seeded out two days before titration. The titration of one cell line required 
48 wells (2x 24-well plate) containing confluent CV-1 cells. 
Before starting the dilution series, the samples underwent a three times freeze-
thaw process. They were thawed in the 37°C heating block and were frozen in 
liquid nitrogen in turns. Dilution series was performed in a 48-well plate, diluting 
the respective sample in 1:10 dilution steps to the necessary dilution levels 
(Table 13). Useful levels of dilution were identified in a previous trial. 
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Harvest time point [hpi] Levels of dilution series 
inoculum pure; 10-1; 10-2 ; 10-3 
1 pure; 10-1; 10-2; 10-3 
24 10-1; 10-2; 10-3; 10-4 
48 10-3; 10-4; 5x10-4; 10-5 
72 10-4; 5x10-4; 10-5; 10-6  
96 10-4; 5x10-4; 10-5; 10-6 
Table 13. Viral dilution series for virus titration on CV-1 cells 
 
After having finished the dilution series, DMEM-10 was removed from the CV-1-
cells in the 24-well plates and replaced by 200 µl of each prepared dilution in 
duplicates. Incubation was performed for one hour at 37°C in 5% CO2 while 
plates were gently moved every 20 minutes. Afterwards cells were covered with 
1 ml DMEM-5 overlay medium containing 1.5% carboxymethylcellulose (CMC) 
per well to avoid virus spreading and incubated at 37°C for another 48 hours. 
Crystal violet stain was performed 48 later. 1 ml crystal violet was added 
carefully on top of the overlay medium per well. Plates were incubated for 3 to 6 
hours or overnight at RT. Afterwards the crystal violet and the overlay medium 
were removed from the wells under the hood and the plates were washed with 
sterile water until the washing solution remained almost clear. The high 
concentrated formaldehyde washing solution was disposed of as hazardous 
waste. To dry the plates after the washing steps, they were gently tapped on a 
towel and left on a fresh towel with the openings down for some minutes at RT. 
 
2.10.2.4 Analysis of Plaque assay results 
Plaque counting took place when the plates were dry. The unstained plaques 
could be detected in the violet stained cell layer of CV-1 cells with the naked 
eye. Plaques were only counted in those wells containing 10-80 plaques. One 
plaque was caused by one virus particle, so the viral titer in the respective 
sample could be directly calculated by the plaque count per well by the following 
formula: 
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[ ] ( ) dilutionofinversedilutionpercountplaqueaveragemlpfutiterviral ××= 5/
 
 
cell line time 
point 
dilution well 
1 
well 
2 
av. PFU/ml Inverse of 
dilution 
Viral titer 
[PFU/ml] 
average 
viral titer 
CC531s 96 
hpi 
1E-04 89 92 90.5 452.5 1E+04 4.53E+06 7.91E+06 
  5E-04 39 36 37.5 187.5 5E+04 9.38E+06 
  1E-05 13 18 15.5 77.5 1E+05 7.75+E06 
  1E-06 1 3 2 10 1E+06 1.00E+07 
Table 14. From plaque assay count to viral titer 
Plaques of the four dilutions of the 96 hpi-sample were counted, mean was multiplied with factor 
5 and with inverse of dilution. Mean of viral titers was 7.91E+06. 
 
Mean of plaque count in well 1 and 2 was multiplied with the factor 5 to obtain a 
total volume of 1 ml (cells were infected in 200 µl DMEM-2). The result was 
multiplied with the inverse of dilution. Viral titer was indicated in [pfu/ml]. 
 
 
Figure 18. 24-well plate after crystal violet staining showing varying numbers of plaques 
Plaques were counted in all wells except A1, B1, C2, D2, C6 and D6. These wells were 
irrelevant for viral titer determination because of either too high or too little plaque count. 
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2.11 Quantification of CD46-receptor expression by flow 
cytometry 
 
Materials for flow cytometry  
Accutase PAA Laboratories 
FACS-buffer (PBS with 10% FCS) - 
Fc-blocking solution Gamunex - 
sotype control eBioscience Inc. 
Anti-CD46-PE (Phycoerythrin) eBioscience Inc. 
Flow cytometer Becton Dickinson FACSCalibur 
Table 15. Materials for flow cytometry 
 
In tumor cells, CD46, a complement regulatory molecule, is often over-
expressed to protect the cells from complement mediated cell lysis. This is one 
reason for the high level of infection of tumor cells by many established measles 
virus vaccine strains which use CD46 as an entrance to the cell. To detect and 
quantify the amount of CD46 on tumor cell surface, cells were marked with anti-
CD46-antibodies and the fraction of CD46+-cells was detected using the flow 
cytometer.Flow cytometry is a method for quantitative detection of cell surface 
and intracellular proteins, DNA and peptides. Only few molecules emit intrinsic 
fluorescence, so most of the molecules like ours must be labelled with a special 
dye or fluorescence labelled antibodies. The labelled molecules separately pass 
the flow cell of the flow cytometer where they become activated by a laser 
beam. The photomultiplier detects the emitted fluorescence light and the light 
diffusion. The amount of light diffusion directly correlates with the size and the 
complexity of a cell. In our experiment, cluster of differentiation (CD) molecules 
were detected at the basis of an antigen-antibody-reaction. 
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Figure 19. Labelling of a CD46+ cell with anti-CD46-antibody and Phycoerythrin (PE) 
 
For fluorescence activated cell sorting (FACS)-staining cells were detached 
with accutase. 6x105 cells were used and resuspended in 50 µl FACS buffer. To 
block Fc receptors 10 µl Gamunex was added. After 5 min incubation on ice, 
cells were stained with Phycoerythrin (PE) conjugated anti-CD46-antibody or 
the corresponding isotype control. PE is one of the most common antibody-
labelling-dye for FACS analysis. One PE molecule is likely to binding one 
antibody molecule. After 30 min incubation on ice 3 ml PBS were added and the 
tubes were centrifuged as before. The cell pellet was resuspended in 500 µl 
FACS buffer. Until measurement, samples were stored on ice or when 
measurement took place the next day cells were fixed with 1.3% PFA. 
Measurement was done using the flow cytometer and the program CellQuest. 
Analysis was done with the software WinMDI and results were presented in a 
histogram (4.2). 
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3 Results 
3.1 Electron microscopy of MeV-SCD/ GLV-1h68 replication 
3.1.1 MeV-SCD replication in A673 and BRZ sarcoma cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Electron microscopy of MeV-SCD infected A673 cells 
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A673 cells were infected with MeV-SCD at MOI 1 or remained uninfected. The normal cell 
structure of a mock-infected A673 cell with intact cell membrane, mitochondria (M), rough 
endoplasmic reticulum and the nucleus (N), including two nucleoli (Nn), is shown (A). Two 
aggregates of viral inclusion bodies within the cell 24 hpi with MeV-SCD at MOI 1 are shown in 
a lower (B) and a higher magnification (C). 48 hpi the chromatin condensation in A673 cell 
nuclei (D, arrows) was the first sign of apoptosis in the infected cells. In another cell, the 
process of disintegration has already started and the inner cell morphology seems to be 
completely out of order (E). Another sign of disintegration is the presence of several 
autophagosomes (arrows) in F. 
 
A673 cells were infected with MeV-SCD (3.3.1) at a multiplicity of infection 
(MOI) of 1 or remained uninfected. Virus infection and production of new viral 
bodies had already started 24 hours post infection (hpi) (B). Signs of viral 
infection were aggregates of viral inclusion bodies (B, C) and signs of cell death 
were chromatin condensation (D), disintegrating cells (E) and the formation of 
autophagosomes (F). Cell death in A673 cells appeared first 48 hpi. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. MeV-SCD infection in BRZ cells 
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BRZ cells were infected with MeV-SCD at MOI 1 or remained uninfected. In A, a mock-infected 
normal cell structure is shown including mitochondria (M), an intact plasma membrane and a 
nucleus (N) with nucleolus (Nn). 24 hpi no viral inclusion bodies were detectable (data not 
shown). 48 hpi, BRZ cells showed typical syncytia formation (B, one cell with two nuclei (N)) 
and distributed viral inclusion bodies (C, rounded by a circle). Signs of both necrosis and 
apoptosis such as autophagosomes (Au) became visible (D). 
 
BRZ cells stayed uninfected (A) or were infected with MeV-SCD at MOI 1 or 
remained mock-infected. Viral infection first appeared 48 hpi when viral 
inclusion bodies (C) and typical syncytia formation (B) were observed at first 
sight. Autophagosomes indicated cell death 48 hpi (D). 
 
 
Figure 22. MeV-SCD infection in BRZ cells 
In A, a disintegrated cell which has lost its plasma membrane is shown. In B and C, the debris 
of an apoptotic cell is shown, surrounded by completely assembled viral particles (circle in B, 
arrows in C). One viral particle is instantaneously budding off a BRZ cell in D (arrow). 
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Disintegration of BRZ cells (A) appeared together with the discovery of intact 
new viral particles shown in two different magnifications in B (circle) and C 
(arrows). The moment of one virus particle budding off one BRZ cell was fixed 
in D. 
 
3.1.2 GLV-1h68 replication in CC531s colon carcinoma and SKOV3ip.1 
ovarian carcinoma cells 
3.1.2.1 GLV-1h68 replication in SKOV3ip.1 cells 
 
Figure 23. Electron microscopy photos of a SKOV3ip.1 cancer cell 
SKOV3ip.1 cells were infected with GLV-1h68 at MOI 0.1 or remained mock-infected. Electron 
microscopy photos were taken 24, 48 and 72 hpi. An intact SKOV3ip.1 cell with nucleus (N) and 
endoplasmatic reticulum (ER) is shown. 
 
A SKOV3ip.1 cell with intact plasma membrane, uniform cytoplasm, nucleus 
(N), different stadia of chromatin condensation and endoplasmatic reticulum 
(ER) is shown in a lower (left panel) and a higher (right panel) magnification. 
Photos were taken for comparing studies between non-infected and infected 
cells. 
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Figure 24. GLV-1h68 infected SKOV3ip.1 cell 24 hpi 
This SKOV3ip.1 cell, infected with MOI 0.1, shows the presence of three morphologic separated 
viral fabrics called “Guarnierische inclusion bodies” within the cytoplasm (arrows). Three viral 
fabrics in increasing magnification from left to right are presented. 
 
Viral inclusion bodies were first observed 24 hpi. Three viral fabrics besides the 
nucleus in the cytoplasm of the SKOV3ip.1 cell are shown (arrows). Often, 
more than one viral fabric was located in one cell as shown representatively in 
Figure 24. 
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Figure 25. Viral replication in a SKOV3ip.1 cell 48 hpi with GLV-1h68 at MOI 0.1 
Different assembly stages of viral particles in an infected SKOV3ip.1 cell were observed 48 hpi 
(A). Virus assembly starts with a semilunar membrane fragment which grows to a globular 
baby-virus (B). Afterwards, the electron dense nucleoprotein-complex which was produced 
before is incorporated into the semilunar membrane. The resulting particle is now called IEV = 
intracellular enveloped virion. In C, both IEVs (on the right) and further developed forms called 
IMV = intracellular mature virion of GLV-1h68 (left) are shown (arrows). In between the two viral 
particle stadia, mitochondria (M) are shown. 
Image D shows three enlarged IMVs. One of those particles (arrow) already shows the typical 
biconcave core structure and the lateral bodies as it is seen in the schematic drawing of VACV 
(right upper corner). 
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48 hpi early and late stadia of virus assembly in SKOV3ip.1 cells could be 
observed (A, B, C). Three of the last stadium viral particles are shown in D at a 
high magnitude. The detail (D) shows the schematic configuration of an IMV 
virus particle. 
 
 
Figure 26. Virus-production in a GLV-1h68 infected SKOV3ip.1 cell at MOI 0.1 72 hpi 
In A lots of pre-stage GLV-1h68 virions in the cytoplasm are shown. Next to the plasma 
membrane there are some IMVs (intracellular mature virions) which bud off the cell. Such a 
budding scene was magnified in B, where two IMVs bud off the infected cell. Released viral 
particles at different stages of development were observed (C). One IEV lies next to a typical 
brick-shaped virion and a not yet brick-shaped form (arrows). Due to virus infection a 
SKOV3ip.1 cell totally lost its original organization and integration. The nucleus (N) shows 
condensate chromatin and cell cytoplasm appears irregular and lost its uniformity (D). 
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Figure 27. Apoptotic SKOV3ip.1 cells after virus production 
SKOV3ip.1 cells collapsed 48 hpi (A) and 72 hpi (B) after successful release of the progeny 
virions. 
 
 
Figure 28. Apoptosis in virus infected SKOV3ip.1 cells 
In infected cells, mitochondria show typical signs of apoptosis. Two different morphologic 
manifestations are shown (arrows). 
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3.1.2.2 GLV-1h68 replication in CC531s cells 
 
 
Figure 29. Virus production in CC531s cells infected with GLV-1h68 at MOI 0.1 
CC531s cells were infected with GLV-1h68 at MOI 0.1 or remained uninfected. A shows a 
healthy mock infected CC531s cell. In B, 24 hpi a “virus fabric” containing viral proteins is 
shown on the right (arrow) and is magnified in C. Different assembly levels of virus particles are 
shown 24 hpi (D, E and F). The IEVs in E (arrow) are magnified in F. 
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Figure 30. Virus-production in CC531s cells infected with GLV-1h68 at MOI 0.1 24 hpi 
A, B and C show accumulations of mostly IMV-particles within the cytoplasm. The CC531s cell 
in D disintegrated after infection and viral production. 
 
In order to find out more about morphologic steps of both MeV-SCD and GLV-
1h68 replication behaviour, electron microscopy was performed. MeV-SCD 
replication was monitored in A673 and BRZ cells (3.1.1). GLV-1h68 replication 
was monitored in SKOV3ip.1 (3.1.2.1) and CC531s cells (3.1.2.2). We observed 
that GLV-1h68 and MeV-SCD differ a lot in morphology and size due to the 
difference in virus species (1.3, 1.4). In case of GLV-1h68 specifically viral 
development stadia (Figure 25 and 26) became visible in contrast to MeV-SCD 
where simply viral fabrics (Figure 20) and mature virions (Figure 22) were 
observed. 
A B 
C D 
RESULTS 
 55 
Another reason we performed electron microscopy was to find out the reaction 
of infected cells to viral burden. All cell lines showed signs of cell death post 
infection. A673 cells showed clear signs of apoptosis such as chromatin 
condensation and autophagosomes (Figure 20). BRZ cells showed apoptotic 
characteristics like autophagosomes as well and we additionally observed 
syncytia formation as a typical reaction of cells infected with MeV-SCD (Figure 
21). In SKOV3ip.1 cells, disintegration (Figure 27) and two types of apoptotic 
mitochondria were found 72 hpi with GLV-1h68 (Figure 28). CC531s cells had 
already lost their integrity 24 hpi (Figure 30). 
Summing up, MeV-SCD and GLV-1h68 replication was successful in all cell 
lines and led to morphologically intact viral yield. CC531s cells died first 24 hpi 
with GLV-1h68 followed by A673, BRZ 72 hpi with MeV-SCD and SKOV3ip.1 
cells 72 hpi with GLV-1h68. Classic apoptotic cell alterations were observed in 
all cell lines except CC531s. 
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3.2 Quantification of CD46 receptor molecules on tumor 
cells 
 
 
Figure 31. Flow-cytometric quantification of CD46 density on tumor cell surfaces 
Cells were labeled with anti-CD46-PE antibody (white histogram) or incubated with an isotype 
control (red histogram) and were analyzed by flow cytometry. The ratio of the arithmetic mean 
fluorescence index of the white histogram: red histogram was calculated and indicated the 
CD46 expression level on cell surfaces. An arithmetic mean under 20 is considered as marginal 
CD46 expression on the cell surface. Analysis was done using winMDI software. 
 
 
In order to determine the quantities of CD46 receptors on surfaces of tumor cell 
lines specifically addressed in this dissertation we performed cell cytometry. 
Tumor cells were labelled with a PE-linked anti-CD46-antibody or were 
incubated with an isotype control. Fluorescence exerted by PE (Phycoerythrin) 
was measured in flow cytometry (3.12). Cell count of the isotype control is 
shown in the red histogram; anti-CD46-labeled cells are represented in the 
white histogram (Figure 31). 
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CD46 expression was detected on all tested cell lines but expression levels 
differed a lot. The ratio of the arithmetic mean of anti-CD46-stained cells/isotype 
control was calculated to quantify the CD46 expression level on cell surfaces. 
A673 cells had the highest CD46-receptor-density (ratio: 66.54) followed by the 
BRZ cells (ratio: 36.67). Of note, SRH cells (ratio: 15.48) and SCOS cells (ratio: 
17.21) showed a ratio of under 20, which was declared a sign of marginal CD46 
expression. 
 
3.3 Infection efficiency of MeV-GFP and GLV-1h68 
3.3.1 Fluorescence monitoring shows successful infection with MeV-
GFP 
 
A673 cells 
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BRZ cells 
 
Figure 32. Monitoring of MeV-GFP-infection by fluorescence microscopy 
A673 (A, B) and BRZ cells (C, D) were infected at MOI 0.01, 0.1 and 1 or were mock-infected. 
Serial phase contrast and corresponding fluorescence photos were taken 48 and 72 hpi at the 
same magnification. Measuring carriage (white) in the right lower corner represents 1000 µm. 
Mock-infected cells showed no green fluorescence whereas virus-infected cells showed 
increasing fluorescence intensity depending on the MOI. Both A673 and BRZ cells formed 
syncytia 48 hpi (A, C) and BRZ cells showed large syncytia formation 72 hpi (D). 
 
To monitor infection of tumor cells, A673 and BRZ cells were infected with MeV-
GFP which encodes the marker gene for green fluorescent protein (GFP).  
In A673 cells (Figure 32 A, B) there was almost no fluorescence 48 hpi at MOI 
0.01 and low fluorescence at MOI 0.1. At MOI 1, most cells were infected by 
MeV-GFP and emitted green fluorescence. Small syncytia formations were 
visible. At 72 hpi, most cells already had detached and showed the typical 
globular shape of dead cells. All cells showed green fluorescence. 
RESULTS 
 59 
In BRZ cells (C, D) only a small amount of cells was infected at MOI 0.01. More 
cells showed green fluorescence at MOI 0.1 and almost every cell was infected 
at MOI 1.  
72 hpi, all fluorescence photos were dominated by large multinuclear syncytia 
formations. Some scattered syncytia formations were visible at MOI 0.01, but 
most of the BRZ cells had not been infected yet. Syncytia formation was 
increased at MOI 0.1. In the corresponding phase contrast photo one large 
syncytium can be seen in the middle of the photo. The highest syncytia count 
occurred in cells infected with the highest MOI (MOI 1). 
 
Figure 33. Large syncytia-formation of BRZ cells after MeV-SCD-infection 
BRZ cells were infected with MeV-SCD at MOI 0.01. At 72 hpi phase contrast and fluorescence 
photos were taken. The photos are presented in a high magnification. In the middle of the 
photos five large syncytia are shown. 
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3.3.2 Expression of SCD in A673 and BRZ cells in Western blot analysis 
 
Figure 34. Western blot analysis of SCD expression in A673 and BRZ cell lysates 
Tumor cells were either infected with MeV-SCD at MOI 0.1 or mock-infected. 75 µg protein 
(established in Bradford dye assay) of each sample were separated by 12% SDS-PAGE. 
Western blot analysis was done using antibodies raised against SCD and Vinculin. The stably 
transfected hepatoma cell line MH-SCD was used as a positive control (+ control). The 
Vinculin-band was detected at the molecular size of 115 kDa; the SCD band was detected at 35 
kDa. Both A673 and BRZ cells were infected by MeV-SCD and were found to express the virus 
encoded transgenic protein SCD. The SCD-band of A673 cells showed a higher amount of SCD 
expression. No SCD-band was detected in the samples of the mock-infected A673 and BRZ 
cells (negative controls). 
 
Western Blot analysis was done with both A673 and BRZ cells uninfected and 
infected with MeV-SCD. The stably transfected hepatoma cell line MH-SCD was 
used as a positive control. In the mock-infected samples of A673 and BRZ cells, 
no SCD band was detected. Both MeV-SCD infected samples of A673 and BRZ 
cells showed a clearly detectable SCD-specific band at 35 kDa. The SCD-band 
of infected A673 cells was more pronounced than the SCD-band in infected 
BRZ cells. In summary, firstly SCD was expressed in both examined tumor cell 
lines and secondly expression of SCD in infected A673 cells was higher than in 
BRZ cells, which was due to the higher SCD expression in A673 cells than in 
BRZ cells. 
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3.3.3 Relative green fluorescence intensity shows successful infection 
with GLV-1h68 
 
Figure 35. GFP-monitoring of fluorescence intensity in GLV-1h68 infected cell lines 
PLC/PRF/5, CC531s, SKOV3ip.1, SRH and SCOS tumor cells were infected with GLV-1h68 at 
MOI 0.1. GFP-expression was monitored over 96 hpi. All photos were taken at the same 
magnification. The measuring carriage (white) in the lower right corner represents 200 µm. All 
cell lines showed green fluorescence of different extent as a sign of infection by GLV-1h68. 
 
The tumor cell lines were infected with GLV-1h68 as described in 3.3.1. To 
monitor the process of infection, a series of fluorescence photos was taken 24, 
48, 72 and 96 hpi. It is obvious that all the tested cell lines, PLC/PRF/5, 
CC531s, SKOV3ip.1, SRH and SCOS were infected by GLV-1h68 and 
expressed the green fluorescent reporter protein. 24 hpi, there was almost no 
green fluorescence except in CC531s cells. 48 hpi PLC/PRF/5, CC531s and 
SKOV3ip.1 cells showed high intensities of green fluorescence throughout the 
infected wells. SRH and SCOS were also infected but only little green 
fluorescence was visible. Green fluorescence in SKOV3ip.1 and SRH cells 
increased 72 hpi. 96 hpi all cell lines emitted green fluorescence in different 
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intensities. CC531s cells expressed most GFP followed by SKOV3ip.1 and 
PLC/PRF/5 cells. SRH and SCOS expressed less GFP than the other tumor cell 
lines which can be explained by the lower cell division rate which was monitored 
in phase contrast microscopy (data not shown). Summing up, infection with 
GLV-1h68 and subsequent GFP expression was successful in all tested tumor 
cell lines. 
 
Figure 36. Measurement of infection kinetics in GLV-1h68 infected SKOV3ip.1 cells 
SKOV3ip.1 cells were infected with GLV-1h68 at MOI 0.1 or remained uninfected. Both phase 
contrast and fluorescence photos were taken at different time points at the same magnification. 
The mock-infected cells grew to confluence (phase contrast) whereas the GLV-1h68 infected 
cells died and detached. The fluorescence photos show successful infection of SKOV3ip.1 cells 
already visible at 24 hpi as green fluorescence. 
 
To visualize the progression of infection in SKOV3ip.1, cells were monitored in 
corresponding phase contrast and fluorescence photos (Figure 36). While the 
uninfected SKOV3ip.1 cells grew more and more confluent, an increasing 
number of the cells infected at MOI 0.1 died and detached from the bottom of 
the wells. Green fluorescence intensity and the amount of infected cells rose 
during the first 72 hpi. 96 hpi most of the cells had detached (as indicated by 
their globular shape) but still emitted green fluorescence. To differentiate 
between dead and vital cells we took advantage of the fact that dead cells have 
a dark colour whereas vital cells are light-coloured in phase contrast 
microscopy. 
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3.3.4 Visualization of β-galactosidase-expression by X-Gal-conversion 
confirms the results of successful infection with GLV-1h68 
 
 
 
Figure 37. X-Gal-staining of GLV-1h68 infected cells 
CC531s and SKOV3ip.1 cells were infected with GLV-1h68 at MOI 0.1. Brightfield photos were 
taken 6, 12, 24, 48, 72 and 96 hpi. All photos were taken in the same magnification; the 
measuring carriage (black) in the right lower corner represents 1000 µm. Both cell lines showed 
increasing marker gene expression as a sign of successful infection. In CC531s cells, β-
galactosidase (β-gal) activity was detectable earlier than in SKOV3ip.1 cells and ended 72 hpi. 
β-gal-expression in SKOV3ip.1 cells also peaked 48 hpi but lasted until 96 hpi. 
 
In  
Figure 37 brightfield photos of X-Gal stained GLV-1h68 infected CC531s and 
SKOV3ip.1 are shown. 6 hpi, there is only little β-galactosidase (β-gal) activity. 
12 hpi, some more cells already expressed the marker gene β-gal and 
consequently appeared in the typical indigoid blue dye. During the next 12 hpi 
there was a different development in terms of color intensity between the two 
cell lines. 24 and 48 hpi the blue dye spread “explosively” within the CC531s 
cells, which were still adherent to the respective well. The color-appearance of 
the SKOV3ip.1 cells had hardly changed until 24 hpi. Widespread β-gal-
expression had started 48 hpi resulting in a strong blue staining. 72 hpi CC531s 
cells had completely detached whereas SKOV3ip.1 cells still expressed β-gal 
and were stained blue until 96 hpi, when most of the SKOV3ip.1 cells had also 
detached and color intensity declined to a minimum. Summing up, GLV-1h68 
infection was successful in both CC531s and SKOV3ip.1 cells monitored by the 
marker-gene expression using X-Gal staining. 
 
12 hpi 24 hpi 48 hpi 72 hpi 96 hpi 6 hpi 
CC531s 
SKOV3ip.1 
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Figure 38. β-galactosidase expression of GLV-1h68-infected CC531s cells 
CC531s cells were infected with GLV-1h68 at MOI 0.1 and 1 or remained uninfected. The 
brightfield photos were taken at the same magnification; measuring carriage (black) in the right 
upper corner represents 200 µm. Mock-infected cells showed marginal blue color due to 
background activity. β-gal expression in cells infected with MOI 0.1 increased explosively 24 
hpi, so most of the cells were stained blue at this time point. The cells which had been infected 
at MOI 1 also showed increasing marker gene expression which decreased again 48 hpi 
because of cell death. 
 
To obtain a comparison between the treatment with MOI 0.1 and MOI 1, 
CC531s cells were infected with both MOI 0.1 and 1. Then, X-Gal-staining was 
performed 6, 12, 24 and 48 hpi. 12 hpi, infection had widely spread within the 
CC531s cells infected with MOI 1 visible by the blue-stained cells. 24 hpi the 
rest of the still viable cell layer expressed β-gal and was stained blue. Further 
washing and staining steps led to a decreased number of cells which were 
stained blue at 48 hpi. This observation can be explained by the fact that blue 
staining was due to β-gal activity which is equivalent to effective viral infection 
and cell death leading to cell detachment as a consequence. 
In cells infected with MOI 0.1, β-gal expression was marginal at 12 hpi but 
increased to a high expression level at 24 and 48 hpi. There were a high 
number of infected cells which expressed β-gal and were consequently stained 
blue. Cells still clung to the bottom of the plate at this time point. Infection with 
GLV-1h68 at MOI 1 led to an earlier cell death of CC531s cells which became 
apparent in the higher intensity of X-Gal staining in cells infected with MOI 0.1. 
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We observed that a lower MOI 0.1 led to an effective viral spread and less 
direct cell death until 48 hpi whereas higher MOI 1 obviously infected and killed 
cells before they were able to spread. β-gal expression was observed earlier 
and GLV-1h68 spreading was self-limited because most of the cells had died at 
48 hpi. 
 
3.4 Replication behaviour of MeV-SCD and GLV-1h68 
3.4.1 Growth curve of MeV-SCD in A673 and BRZ cells 
 
Figure 39. MeV-SCD replication in A673 and BRZ cells 
A673 and BRZ tumor cells were infected with MeV-SCD at MOI 0.03. Supernatants and lysates 
were harvested 3, 24, 48, 72 and 96 hpi and the amount of resulting viral yield was detected by 
standard titration in Vero cells. Data show one representative experiment of MeV-SCD 
replication in A673 and the mean of two independent experiments in BRZ cells. Error bars show 
SD. Viral titers are represented in the tables on the right. 
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In order to quantify viral replication in A673 and BRZ cells we performed growth 
curves of MeV-SCD. Replication behaviour was measured over a time span of 
96 hpi. During the first 24 hpi there was hardly an increase in viral count. 
Between 24 and 48 hpi the number of viral particles increased by a factor of 103 
in both cell lysates and supernatants. Thereafter, the virus replication in both 
cell lines nearly stagnated but reached a maximum viral yield of almost 104 
PFU/ml in lysate 96 hpi and in supernatant 72 hpi in A673 cells. In BRZ cells, 
viral titers increased up to a maximum of about 105 PFU/ml in both supernatant 
and lysate. This was a tenfold higher production of viral particles in supernatant 
and a 100-fold higher virus production detected in cell-lysates in BRZ cells than 
in A673 cells 96 hpi. Viral replication in both cell lines led to a straight viral titer 
increase to 107 PFU/ml in case of A673 cells and to approximately 2x105 
PFU/ml in BRZ cells (cell-supernatant and cell-lysate in addition). 
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3.4.2 Growth curve of GLV-1h68 in CC531s and SKOV3ip.1 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40. Replication behaviour of GLV-1h68 in CC531s and SKOV3ip.1 cells 
CC531s and SKOV3ip.1 cells were infected with GLV-1h68 at MOI 0.1. The rest of the inoculum 
was frozen immediately post infection at -80°C and the cells containing the viral yield were 
harvested and frozen 1, 24, 48, 72 and 96 hpi. All samples underwent three freeze-thaw-cycles 
and virus titration was performed on CV-1 cells. Diagrams show the mean of three independent 
experiments, error bars represent SD. Exact viral titers are shown in the corresponding tables 
on the right. 
 
As previously done with MeV-SCD replication behaviour of GLV-1h68 was 
analyzed in growth curves. Viral replication started immediately post infection (1 
hpi) and increased by the factor 103 within the first 24 hpi in CC531s cells. 48 
hpi, a viral titer of 5.08E+06 PFU/ml was detected by viral plaque count. Viral 
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replication nearly reached a plateau and a maximal viral titer was measured 96 
hpi as 7.58E+06 PFU/ml. 
GLV-1h68 replication behaviour in SKOV3ip.1 cells was similar. The number of 
viral particles increased most strikingly during the first 24 hpi to a titer of 
1.94E+05 pfu/ml. As it was seen in CC531 cells, virus production continued to 
increase tenfold during the next 24 hours and almost stagnated during the last 
48 hpi. The highest titer of 1.59E+07 PFU/ml in SKOV3ip.1 cells was detected 
96 hpi. Summing up we could observe that viral replication started without delay 
immediately post infection and resulted in high titer-increase which is quite 
typical for vaccinia virus infections. 
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3.5 Measurement of cytotoxic effects of virus-infection 
3.5.1 Suicide gene plus 5-FC enhances the cytotoxic effect of MeV-SCD 
3.5.1.1 A673 and BRZ cells were susceptible to 5-FU treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41. 5-FU treatment of tumor cell lines to ensure susceptibility 
5-FU treatment of A673 and BRZ cells was performed to detect the susceptibility to the common 
chemotherapeutic 5-FU. Cells were treated with increasing concentrations of 5-FU and cell 
mass in % of control was measured 72 hpi by SRB assay. One representative of three 
independent experiments performed in triplicates is shown. Error bars represent SD. Both A673 
and BRZ cells were sensitive to 5-FU and cell mass started visible decrease at the 5-FU-
concentration of 10-2 mM (arrow). 
 
Before starting the suicide gene therapy with MeV-SCD combined with the 
prodrug 5-FC, the cell lines A673 and BRZ were tested for susceptibility to 5-
FU, the toxic metabolite of the harmless prodrug 5-FC. Susceptibility to 5-FU 
was considered a precondition for suicide gene and 5-FC treatment. 
Approximately all A673 cells survived the treatment with increasing 
concentrations of 10-6-10-3 mM 5-FU and cell mass had hardly decreased. 
Treatment with 10-2 mM 5-FU reduced the cell mass to about 35% and the 
highest concentration of 1 mM 5-FU led to a remaining cell mass of about 5% of 
control. 
BRZ cells showed the same phenomenon under the treatment at the lower 
concentrations 10-6-10-3 mM 5-FU. Cell mass decreased from 100% to 30% of 
control after treatment with 10-2 mM 5-FU. Increasing concentrations of 10-1 and 
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1 mM 5-FU led to a remaining cell mass of only 15% of control. Thus both A673 
and BRZ cells were susceptible to 5-FU. The minimal effective dose of 5-FU 
was at a concentration of 10-2 mM 5-FU. 
3.5.1.2 Examination of MeV-SCD cytotoxicity in A673 and BRZ cells 
 
 
 
 
 
 
 
Figure 42. Measurement of A673 and BRZ cell mass decrease after MeV-SCD infection 
SRB-assay was performed to assess cell viability of A673 and BRZ cells after infection with 
MeV-SCD combined with 5-FC treatment. Values are presented as percentages of uninfected 
controls, which represent 100% cell viability. Mean of three independent experiments performed 
in quadruplicates with both A673 and BRZ cells are shown, error bars display SEM. A673 cells 
died under the combination treatment with all three MOIs. BRZ cells died to a significant lower 
extent and cells treated with MOI 1 were only reduced to 20% of control by the combination with 
the highest concentration of 1 mM 5-FC. 
 
As it was shown in the previous experiment, A673 and BRZ cells were 
susceptible to 5-FU. Cell viability post MeV-SCD infection was measured using 
SRB-assay ( 
 
Figure 42). 
The sole treatment with 5-FC neither had an effect on A673 cells nor on BRZ 
cells (100% cell mass remaining). The sole treatment with MeV-SCD showed 
little response at MOI 0.01 and 0.1 in BRZ cells whereas the highest MOI 1 led 
to massive cell mass reduction. A673 cell mass was more affected by MeV-
SCD treatment alone. With MOI 0.01, almost half of the cells were killed, the 
use of MOI 0.1 led to a reduction of cell mass of about 60% of control and MeV-
SCD at the highest MOI 1 killed almost 80% of the cells without utilizing the 
suicide gene function. 
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The addition of increasing concentrations of 5-FC resulted in a visible 
improvement of cell-killing except for MeV-SCD at MOI 0.01 in BRZ cells and 
MeV-SCD at MOI 1 in A673 cells. BRZ cell mass treated with MOI 0.01 was not 
affected by the dose escalation of 5-FC and stayed the same as in the 
untreated control. At MOI 1 A673 cell mass was strongly reduced by MeV-SCD 
alone and the addition of 5-FC had only marginal effect. 
1 mM 5-FC led to a successful cell-mass-reduction in combination with MeV-
SCD treatment at MOI 1 in BRZ cells and at all MOIs in A673 cells. 
 
 
 
 
 
 
 
Figure 43. Cytotoxic effect of MeV-SCD and 5-FC on A673 and BRZ cells in vitro 
LDH assay was performed to show the cell lysis caused by MeV-SCD in combination with the 
prodrug 5-FC. Measurement took place 96 hpi using LDH-release as a cell death marker. 
Results were calculated as indicated in 3.10.2. Data represent mean of three (A) and four (B) 
independent experiments performed in quadruplicates. Error bars represent SEM. 
The treatment with MOI 0.01 led to minimal LDH-release in both cell lines similar to the LDH-
release in mock infected cells. A673 cells exhibited strong LDH-release at MOI 1 and to a lower 
extent at MOI 0.1. BRZ cells in contrast showed only little and paradoxical response to the 
treatment with the inserted 5-FC concentrations. 
 
To confirm the data obtained from SRB assay, LDH-release assay was 
performed. Whereas SRB assay gives an overview of cell mass reduction, LDH 
assay measures LDH activity caused by cell death related LDH-release less 
background LDH activity. 
Mock-infected A673 cells showed minimal LDH-release as a matter of basal cell 
death within 96 hours. Cells infected with MeV-SCD at MOI 0.01 showed no 
difference in LDH-release in comparison with mock-infected cells whereas cells 
infected with MOI 0.01 in combination with 5-FC showed a minimally increased 
LDH-release compared to mock-infected cells. Infection with MeV-SCD at MOI 
0.1 led to an increase in LDH-release to nearly 20% and the addition of 5-FC 
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led to a LDH-release of nearly 40%. Infection with MOI 1 resulted in almost 55% 
LDH-release and could be increased to nearby 60% using 1 mM 5-FC 
additionally.  
LDH-release in mock-infected and in BRZ cells infected with MOI 0.01 and 0.1 
was almost the same extent. Infection with MeV-SCD at MOI 1 showed a 
paradox LDH-release response in all four independent experiments. With 
regard to SRB assay results we had expected increasing LDH-release following 
increasing MOI and 5-FC concentration. Contrary to our expectation, LDH-
release actually increased with rising MOIs but decreased with rising 5-FC 
concentrations. 
 
 
 
Figure 44. Alternative treatment of BRZ cells with 5-FC 48 hpi to enhance viral replication 
To lengthen the process of viral replication in BRZ cells, 5-FC was added 48 hpi as an 
alternative to 5-FC treatment ab initio. There was no significant change in LDH-release 
compared to the previous experiments. One independent experiment is shown, error bars 
represent SD. The labelling of the Y-axis was shortened to 30% instead of 100% LDH-release. 
 
As it has been shown that addition of prodrug immediately after infection can 
inhibit virus replication and thus lead to reduced cytotoxic effects (Ungerechts et 
al., 2007), an alternative protocol where 5-FC was added at 48 hpi was tested. 
But the results shown in Figure 44 indicate that no significant change in LDH-
release was detected. Infection with MeV-SCD at MOI 0.01 and 0.1 without 
prodrug and MOI 0.1 plus 5-FC 48 hpi only led to minimal LDH-release and 
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treatment with MOI 1 alone and MOI 1plus 5-FC 48 hpi amounted to the same. 
The addition of 5-FC 48 hpi did not lead to an improvement in terms of 
cytotoxicity. 
3.5.1.3 SRH cells showed strong resistance phenomena to MeV-SCD 
treatment 
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Figure 45. SRH cells survived MeV-SCD treatment with high MOI 1 
SRH cells were infected with MeV-SCD at MOI 0.01, 0.1 and 1 or remained uninfected. Cell 
mass was measured using SRB assay. Data show the mean of three independent experiments, 
error bars represent SEM. The treatment with MeV ld-SCD alone (0 mM 5-FC) revealed primary 
resistance to MeV-SCD as more than 50% of the cells survived. The combination treatment of 
MeV ld-SCD with a maximum concentration of 1 mM 5-FC led to a cell mass reduction of about 
30% at MOI 0.01, 55% at MOI 0.1 and of 60% at MOI 1. 
 
Whereas A673 and BRZ cells died after MeV-SCD infection ( 
 
Figure 42), SRH cells which were clinically tested resistant to chemotherapy, 
showed a different reaction after infection with MeV-SCD. More than 50% of the 
SRH cells survived the infection with MeV-SCD at MOI 1 96 hpi. So SRH cells 
showed a primary resistance to MeV-SCD infection. The treatment with the 
increasing 5-FC concentrations of 0.0001 mM to 1 mM combined with MeV-
SCD infection showed a reduction of cell mass to (i) 70% at MOI 0.01, (ii) 45% 
at MOI 0.1 and (iii) 40% at MOI 1. The remaining cell mass was too high to 
declare the treatment with MeV-SCD successful. So the use of an extremely 
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high MOI of 10 was considered to be the next step in searching for an effective 
instrument against SRH cells. 
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Figure 46. High MOI 10 combined with 1 mM 5-FC kills SRH cells 144 hpi 
SRH cells were infected with MeV-SCD and were treated with 5-FC. The mean of three 
independent experiments is plotted, error bars show SEM. At the low MOI 0.1 and the high MOI 
1, SRH cells showed primary resistance to MeV-SCD treatment. MeV ld-SCD at MOI 10 killed 
about 70% of the cells without addition of 5-FC. Increasing additional 5-FC concentrations led to 
decreasing cell mass. MeV-SCD at MOI 10 plus 1 mM 5-FC successfully reduced cell mass to 
10% of control. The lengthened treatment up to 144 hpi led to a finally remaining cell mass of 
5% of control.  
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In order to find a strategy to kill SRH cells with MeV-SCD, we tested another 
two different treatment options to find the best possible cell mass reduction. 
Firstly we increased the MOI to 10 and secondly we lengthened the process of 
incubation post infection to 144 hpi. We combined both strategies and 
incubated SRH cells after infection with MOI 10 for 144 hours. The treatment 
with MOI 1 without 5-FC showed little cell mass reduction to 75% cell mass 96 
hpi and 65% cell mass 144 hpi. The combination treatment with MOI 1 and 1 
mM 5-FC showed a clear decrease in cell mass to 40% cell mass 96 hpi and 
20% cell mass 144 hpi. Infection with MOI 10 resulted in same results as in the 
trials with MOI 1 and 1 mM 5-FC 96 and 144 hpi. MOI 10 plus 5-FC led to a 
continuous decrease in cell mass over time to 20% of the control SRH cell mass 
96 hpi and to 0% SRH cell mass 144 hpi. 
RESULTS 
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3.5.1.4 SCOS cells resisted MeV-SCD treatment even at MOI 10 
 
 
 
 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 47. SCOS cells resisted combination treatment with MeV-SCD at MOI 10 
SCOS cells were infected at MOI 0.1, 1 and 10 or remained mock-infected. 3 hpi cells were 
treated with different concentrations of 5-FC. Cell mass was determined 96 hpi (A) or daily until 
144 hpi (B). Diagram A shows the mean of two independent experiments, diagram B shows one 
independent experiment, error bars represent SD. 
96 hpi, cell mass of SCOS cells treated with MOI 1 and 1 mM 5-FC was reduced to 60% (A). 
The extension of incubation time to 144 hpi led to a further reduction of SCOS-cell mass to 50% 
in cells treated with MeV-SCD and 5-FC in combination. The infection with MeV-SCD at MOI 1 
and 10 without addition of 5-FC only decreased cell mass to 90% of control 144 hpi. 
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SCOS cell line was derived from another sarcoma which showed therapy 
resistance in the clinical setting like SRH. In order to find a solution to this 
resistance phenomenon we used our MeV-SCD vector for SCOS infection. 
SCOS cells showed an even higher resistance towards MeV-SCD infection than 
SRH and were also declared primary resistant to MeV-SCD (according to the 
resistance definition specified by Tübingen virotherapy lab (AG Lauer)). The 
combination of MOI 1 with 1 mM 5-FC could enhance the cytotoxic effect in 
contrast to solely virus-treatment but cell mass was only reduced to 50% of 
control 144 hpi. MOI 10 and 1 mM 5-FC reduced cell mass to 55% of control. 
Summing up, both SRH and SCOS tumor cells were found to be primary 
resistant to MeV ld-SCD treatment. So as to find an effective strategy to kill 
SRH and SCOS cells, alternative employment of the vaccinia vaccine virus 
GLV-1h68 treatment was the next step to try to overcome the resistance of SRH 
and SCOS tumor cells. We defined two aims for further treatment; firstly another 
vector system should be found to overcome resistance and secondly the high 
MOI 10 which according to current capabilities in vector production cannot be 
reached in human cancer patients should be reduced to a maximum of MOI 1. 
RESULTS 
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3.5.2 GLV-1h68 shows a highly oncolytic potency 
3.5.2.1 Cytotoxic effect of GLV-1h68 on SRH cells which survived MeV-
SCD treatment with high MOIs 
 
 
Figure 48. Cytotoxic effect of GLV-1h68 on SRH cells 
SRH cells were infected with GLV-1h68 at MOI 0.1 and MOI 1 or remained uninfected. SRB-
data (A) and LDH-data (B) show the mean of three independent experiments each, error bars 
represent SEM. GLV-1h68 effectively reduced cell mass to 25% of control at the low MOI of 0.1 
and to less than 10% of control at MOI 1 96 hpi (A). In LDH-release assay cells showed 
proceeding increase in LDH-release over time resulting in 50% LDH-release at MOI 0.1 and 
80% LDH-release at MOI 1 96 hpi. 
 
SRH cells, which were classified as primary resistant to MeV-SCD, were treated 
with GLV-1h68 using MOI 0.1 and MOI 1. Figure 48 A shows the reduction of 
SRH cell mass to 25% of control at MOI 0.1 and to less than 10% at MOI 1 96 
hpi. No resistance phenomenon was found when challenged. LDH-release 
assay (B) confirmed the findings in SRB-assay. LDH-release increased steadily 
over time to 50% in samples treated with MOI 0.1 and 80% in the samples 
treated with MOI 1 96 hpi. These experiments clearly demonstrated that the 
MeV-SCD resistant SRH cells reacted sensitive to GLV-1h68 at both MOIs and 
cell mass was reduced to less than 10% of control 96 hpi. Thereby, the 
necessity of “customized” approaches in virotherapeutic treatment of cancer 
patients is underlined in a most concrete way.  
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3.5.2.2 Cytotoxic effect of GLV-1h68 on PLC/PRF/5 cells 
 
 
Figure 49. Cytotoxic effect of GLV-1h68 on PLC/PRF/5 cells 
PLC/PRF/5 cells were infected with GLV-1h68 at MOI 0.1 and 1 or remained mock-infected. 
Cell death was measured in SRB and LDH assay, one representative experiment is shown in A 
and the mean of three independent experiments is shown in B. Error bars show SEM. GLV-
1h68-treatment with MOI 0.1 led to a remaining cell mass of 30% 96 hpi. GLV-1h68 at MOI 1 
led to a cell mass reduced to 10% 96 hpi (A). Increasing LDH-release (B) to 30% at MOI 0.1 
and to 70% at MOI 1 96 hpi over time confirms increasing cell death with increasing time-span 
post infection and higher MOI as it was previously shown in A. 
 
Besides the human sarcoma cell lines SRH and SCOS which were hard to treat 
in clinic, we also focused on tumor cell lines likely to cause peritoneal 
carcinosis, another cancer species which is currently not easy to treat.  
We started with the evaluation of the PLC/PRF/5 human hepatoma cell line as 
hepatomas sometimes spread into the peritoneal cavity. PLC/PRF/5 cells were 
infected with GLV-1h68 at MOI 0.1 and 1 or remained uninfected. Cell mass in 
wells infected with MOI 0.1 decreased to nearly 30% of control and cell mass of 
cells treated with MOI 1 was reduced to 10% 96 hpi Figure 49 A. LDH-release 
assay showed marginal LDH-release in mock-infected cells, 25% LDH-release 
in cells treated with MOI 0.1 and the highest LDH-release up to 70% in cells 
infected with MOI 1 96 hpi (B). PLC/PRF/5 cells were successfully killed by 
GLV-1h68. 
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3.5.2.3 Cytotoxic effect of GLV-1h68 on CC531s cells 
 
Figure 50. Eradication of CC531s cells by GLV-1h68 
CC531s cells were infected with GLV-1h68 at MOI 0.1 and MOI 1 or remained mock-infected. 
Data represent the mean of three independent experiments, error bars show SEM. Cell mass of 
CC531s cells decreased continuously over time until there was 0% cell mass left 96 hpi with 
both MOI 0.1 and 1 (A). In LDH-release assay acknowledged this data showing high LDH-
release under GLV-1h68 treatment of 60% at MOI 0.1 and 90% at MOI 1 96 hpi. 
 
The colorectal carcinoma cell line CC531s of rat origin represents another 
cancer species likely to spread into the peritoneal cavity and is widely used in 
syngeneic animal models of peritoneal carcinosis. CC531s cells were infected 
with GLV-1h68 at MOI 0.1, 1 or remained uninfected. Cell mass of cultures 
treated with MOI 0.1 and MOI 1 was reduced to 0% of control 96 hpi (A). The 
high LDH-release rates of 60% at MOI 0.1 and 90% at MOI 1 were also 
indicators for the strong cytotoxic effect of GLV-1h68 on CC531s cells (B). 
CC531s cells were successfully killed by GLV-1h68. 
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3.5.2.4 Cytotoxic effect of GLV-1h68 on SKOV3ip.1 cells 
 
 
Figure 51. Cytotoxic effect of GLV-1h68 on SKOV3ip.1 cells 
SKOV3ip.1 cells were infected with GLV-1h68 at MOI 0.1 and 1 or remained uninfected. Three 
independent experiments were performed and data show mean and SEM. The oncolytic 
potency of GLV-1h68 led to a decrease in cell mass of 70% at MOI 0.1 and of 90% at MOI 1 96 
hpi. Data of LDH-release show the expected increase in LDH-release in conformity with 
decrease in cell mass. LDH release in cells infected with MOI 0.1 rose to 40% and cells infected 
with MOI 1 released about 70% of the available LDH in total 96 hpi. 
 
Human SKOV3ip.1 cells displayed ovarian cancer as another tumor entity likely 
to spread into the peritoneal cavity and are also widely used in xenograft animal 
models of peritoneal carcinosis. SKOV3ip.1 cells were infected with GLV-1h68 
at MOI 0.1 and MOI 1 or remained uninfected (Figure 51). SRB assay revealed 
a reduction of cell mass to 35% of control in cells infected with MOI 0.1 and a 
reduction to 10% of control in cells infected with MOI 1 96 hpi (A). Increasing 
LDH-release to 40% at MOI 0.1 and up to 70% at MOI 1 (B) confirmed the 
findings of the SRB assay. 
 
Up to this point, there were no resistance phenomena towards the GLV-1h68-
treatment observed and GLV-1h68 was able to overcome any problems 
observed in MeV-SCD-based oncolytic treatment of SRH cells. The next step 
was to evaluate the cytotoxic effect of GLV-1h68 in SCOS cells, which also 
were shown to be resistant to MeV-SCD infection as demonstrated in 3.5.1.4.  
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3.6 The discovery of partially GLV-1h68-resistant cell-lines 
3.6.1 Cytotoxic effect of GLV-1h68 on SCOS-cells 
 
 
Figure 52. Cytotoxic effect of GLV-1h68 on SCOS cells 
SCOS cells were infected with GLV-1h68 at MOI 0.1 and 1 or remained uninfected. SRB (A) 
and LDH assay (B) were performed. Data show the mean of three independent experiments 
each, error bars represent SEM. Cell mass of SCOS cells treated with MOI 0.1 was reduced to 
75% of control and cell mass of SCOS cells treated with MOI 1 was reduced to 35% of control 
96 hpi (A). LDH-release increased to 15% 96 hpi with MOI 0.1 and to 30% 96 hpi with MOI 1 
(B). 
 
SRB assay revealed that cell mass of SCOS cells was nearly reduced to 75% of 
control at MOI 0.1 and to almost 35% of control at MOI 1 96 hpi. So SCOS 
partially resisted the infection and oncolytic effects with GLV-1h68. LDH-release 
stayed minimal at MOI 0.1 throughout the duration of the experiment nearly 
according to the measured background LDH-release in the mock-infected cells. 
LDH-release in cells treated with MOI 1 reached an extent of 30% 96 hpi. These 
results in cell viability assays showed, that GLV-1h68-treatment alone was not 
sufficient to efficiently kill SCOS cancer cells.  
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3.7 Virotherapy using the armed GLV-1h95 led to a stronger 
cytotoxic effect than GLV-1h68-treatment alone 
3.7.1 Cytotoxic effect of GLV-1h95 on SCOS cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 53. GLV-1h95 combined with 5-FC showed highly cytotoxic effect on SCOS cells 
SCOS cells were infected with GLV-1h95 at MOI 0.01, 0.1 and 1 or remained uninfected. 
Cells were treated with increasing 5-FC-concentrations from 0.0001 to 1 mM to utilize the 
suicide gene function of armed virotherapeutic GLV-1h95. Cell mass was measured 96 hpi. 
Data show the results of one representative experiment, error bars represent SD. Cell mass of 
both cultures infected with MOI 0.01 and 0.1 plus 1 mM 5-FC was reduced to 50% of control 96 
hpi. Cell mass of cells infected with MOI 1 plus 5-FC was reduced to nearly 20% at 96 hpi. 
 
In order to find an efficient virotherapeutic against SCOS cells, the armed 
vaccinia vector GLV-1h95 was used for further examinations. GLV-1h95 was 
derived from its parental virotherapeutic GLV-1h68 and additionally encodes the 
suicide gene FCU1 in the A56R locus. FCU1 equates the suicide gene SCD in 
MeV-SCD and leads to the conversion of 5-FC into the toxic 5-FU when it is 
successfully expressed in tumor cells post infection. 
SCOS cells were infected with GLV-1h95 and treated with the prodrug 5-FC 
which was metabolized into the toxic 5-FU by SCD expressed by GLV-1h95. 
The higher the MOI and the 5-FC-concentration, the higher was the reduction of 
the SCOS cell mass. MOI 0.01 and 0.1 combined with 1 mM 5-FC only reduced 
the SCOS cell mass to 50% of control. GLV-1h95 at MOI 1 and 1 mM 5-FC led 
to a remaining cell mass of about 25% of control. Compared to the results of the 
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GLV-1h68 effects on the SCOS cells where 35% of the cell mass remained 96 
hpi, cell death could be enhanced, represented in a greater extent of cell mass 
reduction to 20% 96 hpi with GLV-1h95. 
 
3.7.2 Comparison of GLV-1h68 and GLV-1h95 effects 
In a next experiment designed to overcome primary resistances to 
virotherapeutics, the three tumor cell lines HT29 (colorectal carcinoma), SiHa 
(cervical squamous cell carcinoma) and NCI-H1299 (breast adenocarcinoma) 
which were defined as non-responders (NR) in xenograft models by Worschech 
et al. were infected with both GLV-1h68 and GLV-1h95. Infection efficacy using 
GFP expression by GLV-1h68 and cell mass behaviour post infection with GLV-
1h68 and GLV-1h95 was monitored over 96 hours. 
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Figure 54. GFP expression after GLV-1h68-infection via GFP-fluorescence-monitoring 
and phase contrast microscopy 
HT29, NCI-H1299 and SiHa tumor cells were infected with GLV-1h68 at MOI 0.1. Phase 
contrast and fluorescence photos were taken 24, 48, 72 and 96 hpi at the same magnification. 
Measuring carriage in the right lower corner represents 200 µm. Visible infection started 24 hpi 
in NCI-H1299 and HT29 cells, 48 hpi in SiHa and MDA-MB-231 cells. 75% of the HT29 cells, 
growing in adherent cell clusters, showed GFP expression 96 hpi. GFP-expression in NCI-
H1299 cells increased strongly 48 hpi and 100% of the cells expressed GFP from 72 hpi. SiHa 
cells which have a low cell division rate also expressed GFP in nearly 90% of the cells from 72 
hpi. 
 
The three cell lines were infected with GLV-1h68 at MOI 0.1. 5% of the NCI-
H1299 and HT29 cells were the first to express green fluorescent protein (GFP) 
48 hpi. 50% of the SiHa expressed GFP from 48 hpi. HT-29, a cell line which 
grows in small adherent cell-clusters and not as a complete cell layer was totally 
infected 96 hpi but still exhibited adherence. 100% of the NCI-H1299 cells 
expressed GFP 72 hpi and the cells were already morphologically 
predominantly dead at this time point. 50% of the SiHa cells began to emit 
green fluorescence 48 hpi at low intensity. The infection was found to spread 
during the next 48 hours but most SiHa cells remained adherent under GLV-
1h68-treatment at MOI 0.1. Taken these results together, all cell lines tested 
were successfully infected by GLV-1h68 although to different extents. 
RESULTS 
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Figure 55. GLV-1h68 and GLV-1h95 minimize NCI-H1299 cell mass to the same extent 
NCI-H1299 cells were infected with GLV-1h68 at MOI 0.1, 1 or remained mock-infected (A). In a 
second approach, cells were infected with GLV-1h95 at MOI 0.01, 0.1 and 1 or remained 
uninfected. 1 hpi, the cells were treated with increasing 5-FC-concentrations (B). SRB assay 
was performed at different time points (A) or 96 hpi alternatively (B). Data show one 
representative of three independent experiments done in quadruplicates. Error bars represent 
SD. Cell mass was reduced to 5% 96 hpi with GLV-1h68 at MOI 0.1 and 1 (A), and cell mass 
was reduced to 25% (MOI 0.01), 10% (MOI 0.1) and 5% (MOI 1) in combination with 1 mM 5-
FC (B). 
 
In order to compare cytotoxic potency of GLV-1h68 and GLV-1h95 SRB assay 
was performed Figure 55. NCI-H1299 cell mass was reduced to approximately 
5% of control at 96 hpi with GLV-1h68 (A). Infection with the armed virus GLV-
1h95 and the addition of 5-FC resulted in a remaining cell mass of 10% at MOI 
0.1 and 5% at MOI 1 with all 5-FC-concentrations. The lower MOI 0.01 showed 
a minimally weaker effect of 25% remaining cell mass with the use of 1 mM 5-
FC than MOI 0.1 and 1. GLV-1h95 infection without addition of 5-FC resulted in 
similar remaining cell masses of about 10% 96 hpi. Noticeably was the fact that 
cell mass infected with MOI 0.01 and 0.1 increased with increasing 5-FC 
concentrations which we did not expect but were able to reproduce in multiple 
other experiments (B). 
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Figure 56. GLV-1h95 enhances the cytotoxic effect of GLV-1h68 on HT29 cells 
HT29 cells were infected with GLV-1h68 at MOI 0.1 and 1 or remained mock-infected (A). In B, 
HT29 cells were mock-treated or infected with GLV-1h95 at MOI 0.01, 0.1 and 1 and were 
treated with different concentrations of 5-FC 1 hpi. Cell mass was measured 96 hpi (B). Data 
show one representative of three independent experiments respectively, error bars represent 
SD. Cell mass of HT29 cells was reduced to 80% (MOI 0.1) and 20% (MOI 1) with GLV-1h68 
(A) and to 75% (MOI 0.01), 25% (MOI 0.1) and 10% (MOI 1) combined with 1 mM 5-FC 96 hpi 
(B). 
 
GLV-1h68-treatment of HT29 cells at MOI 0.1 led to a resulting cell mass of still 
80% of control at 96 hpi. The remaining cell mass of 60% 72 hpi at MOI 1 was 
only reduced to 20% 96 hpi. But the armed GLV-1h95 was able to enhance the 
cytotoxic effect of GLV-1h68. Cell mass was reduced to 25% of control after 
treatment with MOI 0.1 combined with 1 mM 5-FC and the cytotoxic effect was 
even enhanced by the use of MOI 1 and 1 mM 5-FC which led to a cell mass of 
nearly 10% of control. Thus, HT29 cells were nearly eradicated by GLV-1h95 at 
MOI 1 and 1 mM 5-FC at 96 hpi. 
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Figure 57. GLV-1h95 enhances the cytotoxic effect of GLV-1h68 on SiHa cells 
SiHa cells were infected with GLV-1h68 at MOI 0.1 and 1 or remained mock-infected. In another 
approach, SiHa cells were infected with GLV-1h95 at MOI 0.01, 0.1, 1 or also remained 
uninfected. Increasing concentrations of 5-FC were added. Cell mass was measured at 96 hpi 
(B). Data show one representative of three experiments done in quadruplicates, error bars show 
SD. SiHa cell mass was reduced to 55% with MOI 0.1 and to 15% with MOI 1 96 hpi with GLV-
1h68 (A), and cell mass was reduced to 75% (MOI 0.01), 20% (MOI 0.1) and nearly 0% (MOI 1) 
with GLV-1h95 and the addition of 1 mM 5-FC (B). 
 
SiHa cells treated with GLV-1h68 at MOI 0.1 were reduced to 55% of control 
cell mass 96 hpi. The higher MOI 1 led to a remaining cell mass of 15% at 96 
hpi. The treatment with GLV-1h95 showed a cell mass reduction up to 20% of 
control at MOI 0.1 and a reduction to nearly 0% remaining cell mass at MOI 1 
and 1 mM 5-FC at 96 hpi. As it was shown in HT29 cells, GLV-1h95 could 
enhance the cytotoxic effect of GLV-1h68 in SiHa cells. GLV-1h95 alone at MOI 
0.1 (MOI 1) reduced SiHa cell mass to 20% (15%) at 96 hpi whereas GLV-1h68 
at MOI 0.1 (MOI 1) only reduced cell mass to 55% (5%) at 96 hpi. This shows 
the stronger cytotoxic effect of GLV-1h95 in contrast to GLV-1h68. 
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3.7.3 Replication behaviour of GLV-1h68 in non-responding tumor cell 
lines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 58. Replication behaviour of GLV-1h68 in HT29, NCI-H1299 and SiHa and cells 
HT29, NCI-H1299 and SiHa cells were infected with GLV-1h68 at MOI 0.01. The inoculum (0 
hpi) was frozen immediately and samples of 1, 24, 48, 72 and 96 hpi were frozen too. Plaque 
assay on CV-1 cells was performed in duplicates. Data show the mean of three independent 
experiments, error bars represent SEM. Viral replication yielded a massive titer increase up to 
4.15E+07 pfu/ml (HT29), 2.44E+07 pfu/ml (NCI-H1299) and 4.4E+06 pfu/ml (SiHa) 96 hpi. 
Whereas viral titer increased over time to the highest titer 96 hpi in HT29 and SiHa whereas 
viral titer in NCI-H1299 cells decreased from 8.20E+07 pfu/ml 72 hpi to 2.44E+07 pfu/ml 96 hpi. 
 
As HT29, NCI-H1299 and SiHa cells were designated as cell lines non-
responding to GLV-1h68-based oncolysis by Worschech et al. and SiHa and 
NCI-H1299 were resistant to GLV-1h68-replication during the first 24 hpi, we 
independently re-evaluated these cell lines in order to confirm or refute these 
findings (Figure 58). In our examinations GLV-1h68-replication was monitored 
over 96 hpi. Infection with GLV-1h68 resulted in a steady titer increase in all cell 
lines over time until 96 hpi except in NCH-H1299. Here, viral yield peaked at 
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8.20E+07 pfu/ml 72 hpi and decreased to 2.44E+07 pfu/ml 96 hpi. We observed 
no delay in viral replication behaviour as it was described by Worschech et al. 
GLV-1h68 replicated in all four cell lines and increased to viral titers of 
4.15E+07 pfu/ml (HT29), 2.44E+07 pfu/ml (NCI-H1299) and 4.4E+06 pfu/ml 
(SiHa) 96 hpi. Differences in viral titer can be explained by slower cell division 
rate of SiHa cells which led to the lowest viral titer of 4.4E+06 pfu/ml (SiHa). 
3.8 GLV-1h68 infection of primary human hepatocytes (PHH) 
 
Figure 59. Infection of PHH with GLV-1h68 
PHH were mock-infected or were infected with GLV-1h68 at MOI 0.1 and MOI 1. Phase contrast 
and fluorescence photos were taken at several time points post infection at the same 
magnification. Measuring carriage (white) in the right lower corner represents 200 µm. PHH 
infected with MOI 0.1 expressed GFP in 5% (48 hpi), 5% (72 hpi) and in 30% (96 hpi) of the 
cells. The corresponding phase contrast photos show, that PHH did not detach but grew despite 
viral infection. PHH infected with MOI 1 expressed GFP up from 24 hpi (10% of PHH) and 96 
hpi 90% of PHH expressed GFP. 80% PHH had detached 72 hpi. PHH infected with MOI 1 
predominantly detached but PHH infected with MOI 0.1 were still adherent 96 hpi which could 
be confirmed by SRB assay results (Figure 60). 
 
24 hpi 48 hpi 72 hpi 96 hpi 
MOI 0.1 
MOI 1 
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In order to evaluate potential cytotoxic effects of GLV-1h68 on primary human 
tissues we performed infection experiments with primary human hepatocytes 
(PHH). PHH were infected with GLV-1h68 at MOI 0.1 and 1. Wells infected with 
MOI 0.1 expressed GFP in 5% (48 hpi, 72 hpi) and in 30% (96 hpi) of the cells. 
The corresponding phase contrast photos show, that PHH did not detach but 
grew despite viral infection. PHH infected with MOI 1 expressed GFP in 10% 
(24 hpi) and 90% (96 hpi) of the cells. 80% of the PHH infected with MOI 1 had 
detached 72 hpi. Both MOIs led to GFP expression in fluorescence microscopy; 
notably to a higher extent in PHH when infected with MOI 1. Phase contrast 
photos however revealed that PHH infected with MOI 0.1 grew over time and 
PHH infected with MOI 1 predominantly detached until 96 hpi (Figure 59). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 60. Infection of PHH with GLV-1h68  
PHH cells were infected with GLV-1h68 at MOI 0.01, 0.1, 1 and the high MOI 10 or remained 
mock-infected. Cell mass in % of control was measured 96 hpi by SRB assay. Data show the 
result of one representative experiment, error bars represent SD. PHH cell mass infected with 
MOI 0.01 slightly increased to 105% and PHH mass infected with MOI 0.1 was 100% of control 
at 96 hpi. Cell mass of PHH infected with MOI 1 was reduced to 50% and cell mass infected 
with MOI 10 was reduced to 30% of control. 
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To get a clearer view of PHH cell mass change during the 96 hpi, SRB assay 
was performed. SRB-results indicated that PHH cell mass did not decrease 
under GLV-1h68-treatment at MOI 0.01 and 0.1. The higher MOI 1 
(morphologic change in PHH is shown in Figure 60) led to a reduction in cell 
mass up to 50% of control and GLV-1h68 at very high MOI 10 killed nearly 75% 
of the non-transformed PHH. GLV-1h68 therefore does not exert cytotoxic 
effects to PHH at low MOIs such as 0.01 and 0.1 but kills half of the cells at MOI 
1. Infection with MOI 10 showed highly cytotoxic effects and killed 75% of the 
PHHs. However, when “challenging” human hepatocytes in vitro with 
virotherapeutics it has to be taken into account that under in vivo conditions 
these primary cell lines are living in a three dimensional environment thereby 
being in contact with many other cell types, especially immune cells, which 
through diverse signalling activities efficiently inhibit replication of 
virotherapeutics in non-malignant cells. This perception is supported by our 
recent findings in our virotherapeutic clinical trial currently taking place at 
University Hospital Tübingen (ClinicalTrials.gov Identifier: NCT01443260). 
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4 Discussion 
Cancer is one of the most frequent causes of death in the western world. After 
years of research in order to find novel curative therapy approaches, there is 
still no curative therapy option for many kinds of cancer. Therefore, the need for 
alternative cancer therapy options rises. Besides surgery, chemotherapy and 
radiotherapy which were made standard practice many years ago, novel 
therapy options like virotherapy are on the edge to enter the clinic. When 
Bluming and Ziegler et al. (1971) found out that a Burkitt’s lymphoma in an 
African boy’s face regressed and finally disappeared within weeks in 
association with a natural measles virus infection (Bluming et al., 1971), a proof-
of-principle for oncolytic viruses as anti-cancer treatment option was given by 
nature. Measles virus (MeV) was shown to have an inherited oncolytic potency 
(Grote et al., 2001; Heinzerling et al., 2005; Peng et al., 2001; Phuong et al., 
2003), which was also found for several other viruses like vaccinia virus (VACV) 
(Yu et al., 2004), or Newcastle Disease virus (NDV). To optimize the oncolytic 
efficacy of these viruses, therapeutic transgenes were inserted into the viral 
genome. The Super-CD (SCD) or FCU1 gene, encoding for the prodrug 
converting enzyme SCD (see paragraph 2.5) is one of the best characterized 
suicide genes which were inserted into several viruses like MeV or VACV to 
enhance the oncolytic efficacy of virotherapeutics against colorectal cancer 
(CRC) (Foloppe et al., 2008), breast cancer (Anderson et al., 2000), colorectal 
carcinoma and cholangiocarcinoma (Stackhouse et al., 2000) as well as 
prostate cancer (Freytag et al., 2003). SCD has also been integrated into the 
genome of adenoviruses which have been extensively studied in our lab and in 
many cooperating laboratories and showed significant enhancement of 
oncolytic effects in several studies (Graepler et al., 2005; Lemken et al., 2007; 
Warmann et al., 2006a; Warmann et al., 2006b; Warmann et al., 2009). Besides 
suicide genes which are able to toxify a primarily non-toxic prodrug, other 
therapeutic genes like anti-angiogenic transgenes (Frentzen et al., 2009; Guse 
et al., 2010; Thorne et al., 2006) or immune stimulatory genes (Parker et al., 
2000; Wong et al., 2001) have already been inserted in viral genomes. 
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As there are still severe limitations in the treatment of chemotherapy-resistant 
human sarcomas and peritoneal carcinosis (Arnold et al., 2007), we here 
focused on the sarcoma cell lines A673 (extraosseus Ewing’s sarcoma), BRZ 
(alveolar rhabdomyosarcoma), SRH (sclerosing rhabdomyosarcoma) and 
SCOS (osteosarcoma) and two cancer cell lines used in well characterized 
models of peritoneal carcinosis, CC531s (colorectal carcinoma) and SKOV3ip.1 
(ovarian carcinoma), to investigate state-of-the-art MeV and VACV vector 
systems with regard to their infection and replication behaviour and oncolytic 
efficacies. Both vector systems were applied as a non-armed (MeV-eGFP/GLV-
1h68) and an armed (MeV-SCD/GLV-1h95) version, respectively. 
 
Similar infectability-patterns of cancer cells by MeV and VACV were 
observed monitoring marker gene expression 
In a first step we analyzed the infection rate of both viral vector systems on the 
basis of marker gene expression. While MeV-eGFP contains the marker gene 
eGFP, infections with GLV-1h68 could be monitored using both GFP (ruc-gfp) 
and β-galactosidase (lacZ) expression. 
The expression of GFP in MeV-eGFP infected sarcoma cell lines A673 and 
BRZ started to be detectable 24 hpi, maximizing between 48 and 72 hpi. GFP 
expression decreased 96 hpi due to the break-down of the biosynthesis 
machinery and the detachment of dead cells. It appeared surprising that cells 
infected with MOI 0.1 showed higher green fluorescence intensities than cells 
infected with MOI 1. However, this phenomenon can be explained easily by the 
fact that cell death occurs earlier under the treatment with MOI 1 leading to the 
detachment of the cells. Since GFP expression stops with cell death, 
fluorescence intensity decreased significantly earlier than in cells infected with 
MOI 0.1. 
Green fluorescence intensity in GLV-1h68 infected cells overall appeared much 
weaker than in MeV-SCD infected cells but showed nearly the same behaviour 
concerning the period of GPF expression peaking at 48 to 72 hpi. Lower 
intensities of green fluorescence may be explained by the simple fact that GLV-
1h68 expresses a non-enhanced form of GFP other than MeV-eGFP which 
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expresses an enhanced form of GFP (eGFP). When looking on the expression 
levels of all VACV-endoced marker genes it was found that the gene products 
of the lacZ and the gusA gene, β-galactosidase and β-glucoronidase, as well as 
the product of ruc-gfp, GFP, were expressed in 100% of the experiments. 
Thereby, evidence was provided that GLV-1h68 expresses all inserted marker 
genes on the same level. Results of our XGal-staining investigations, proving 
the expression of β-galactosidase within the infected cells, provided additional 
evidence of successful infection with GLV-1h68 in CC531s and SKOV3ip.1 
cells. Taken together, infection of all cell lines (chemotherapy-resistant human 
sarcomas and peritoneal carcinosis cell lines) with both virotherapeutics MeV 
ld-eGFP and GLV-1h68 was successful. 
Comparing the infection mechanisms of MeV and VACV, CD46 was identified 
as a receptor on cell surfaces for MeV Edmonston vaccine strains (Dorig et al., 
1993; Naniche et al., 1993). In contrast to the well-known entry mechanism of 
MeV strains, there is no special entry molecule on cell surfaces known for the 
entry of VACV. A “problem” in understanding the entry mechanism of VACV are 
the two morphologically distinct infectious forms which are called IMV 
(intracellular mature virus) and EEV (extracellular enveloped virus) (Carter et 
al., 2005). G.C. Carter and M. Law described three envelope proteins of the 
IMVs which bind to glycosaminoglycans (GAGs) on the respective tumor cell 
surface and allow viral entry. But they discovered too that IMVs were also able 
to enter cells in a different way. The one conclusion they made of their 
investigations was that VACV IMVs enter cells via cell-membrane fusion. The 
viral core is subsequently released into the cytoplasm. Vanderplasschen et al. 
(1998) showed, that the entry mechanism of EEVs is dependent on a low-pH 
pathway in contrast to the IMV entry (Van Dorig et al., 2003). In conclusion 
neither IMVs nor EEVs enter tumor cells with the help of one distinct receptor 
(or it has not yet been discovered) making it impossible for us to provide a 
prediction of the GLV-1h68 infection rate by analysis of receptor expression on 
targeted tumor cells. Other than that, we could show that CD46 receptor density 
is closely associated with the level of MeV ld-SCD infection and cell death in the 
respective cell lines. As CD46 is known to be over-expressed on tumor cells in 
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comparison to non-malignant cells in the surrounding tissue, which was shown 
for HCC cells (Blechacz et al., 2006), multiple myeloma cells (Ong et al., 2006) 
and RCC cells (Meng et al., 2010), tumor cells display a favourable target for 
MeV. We determined the CD46 density on tumor cell surfaces using flow 
cytometry to calculate an arithmetic mean established by Anderson et al. 
(2004), which served as an approximate value of CD46 density. In accordance 
with Anderson et al., our experiments offered correlating results between the 
value of the calculated arithmetic mean of CD46 density and the extent of GFP 
expression and cell lysis in the four sarcoma cell lines. A673 cells, exhibiting the 
highest CD46 density, extensively expressed GFP all over the monolayer 48 
and 72 hpi (at MOI 1) and so did the BRZ cells. Moreover, the BRZ cell layer 
presented syncytia formations consisting of multinucleated giant cells after cell-
cell fusion which constitutes a typical CPE (cytopathic effect) for MeV infected 
tumor cells.  
Summing up, our results showed that A673 and BRZ cells exhibited higher 
CD46 densities than SRH and SCOS cells with SCOS cells expressing least 
CD46. The CD46 density could be concordantly correlated to the level of GFP 
expression: the higher the CD46 density, the higher the GFP expression being 
a surrogate parameter for the extent of tumor cell infection. 
 
Detailed analysis of infectability showed successful replication of both 
MeV and VACV 
In Western Blot analysis, the presence of SCD after MeV-SCD infection of the 
cell lines A673 and BRZ was proven. A673 cells showed higher expression of 
SCD enzyme. This might be due to the higher CD46 density on A673 cell 
surface resulting in a higher viral load and consequently higher expression 
levels of the virotherapeutic-encoded SCD transgene. The higher concentration 
of SCD (and 5-FU) in the infected cells might have been responsible for the 
rapid cell death of A673 and BRZ cells after additional treatment with 5-FC: the 
more SCD is expressed, the higher the conversation rate of 5-FC into 5-FU is 
elevated. 5-FU as a “classical” cytotoxic compound triggers cell death. As we 
only analyzed the total amount of intracellular SCD when we performed 
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Western Blot analysis we could not say anything about the functionality of SCD. 
To gain knowledge about the functionality of SCD, a HPLC (high performance 
liquid chromatography) could have been additionally performed to detect the 
conversation rate of 5-FC into 5-FU demonstrating the functionality of the 
converting enzyme SCD. Dr. J. Lampe in our laboratory determined the 
conversion of 5-FC into 5-FU by HPLC in hepatoma cell lines after infection with 
MeV-SCD and addition of 5-FC. In these cells, up to 100% of 5-FC was 
converted into 5-FU (Lampe et al., manuscript submitted). 
The replication of both viral vectors was monitored in vitro by growth curve 
assays. Titration of MeV-SCD in A673 and BRZ cells was performed on Vero 
cells showing increasing viral titres over a period of 96 h in both supernatant 
and cell lysate resulting in viral titres of 107 pfu/ml in case of A673 cells and 
approximately 2x105 pfu/ml in BRZ cells. Replication of GLV-1h68 in CC531s 
and SKOV3ip.1 cells was shown in standard plaque assay titrated on CV-1 
cells. Viral yield peaked at 7.58x106 pfu/ml in CC531s cells and 1.59x107 pfu/ml 
in SKOV3ip.1 cells 96 hpi. The process of both MeV-SCD and GLV-1h68 
replication was also monitored in electron microscopy for the first time (in 
cooperation with the University Clinic of Dermatology Tübingen, Prof. Dr. med. 
Schaller, Mrs. B. Fehrenbacher). Viral fabrics, pre-stages, completed intra- and 
extracellular brick-shaped viral particles and even budding viruses could be 
fixed giving a 100% morphologic evidence of viral reproduction within the tumor 
cells. Besides focusing on viral replication and cell destruction, two different 
morphological forms of apoptotic mitochondria were detected in SKOV3ip.1 
cells 72 hpi with GLV-1h68 pointing to an apoptotic cell death following VACV 
infection as it has already been shown by Seubert C.M. et al. (2011) who 
observed activation of the intrinsic apoptotic pathway after the combination 
treatment of breast cancer cell lines with a β-galactosidase-activatable prodrug 
and GLV-1h68 (Seubert et al., 2011). However, VACV kills cells not only by 
initiating apoptotic pathways but also by other mechanisms e.g. taking over the 
cellular biosynthesis machinery and suppressing the cell’s RNA-, DNA- and 
protein synthesis. 
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GLV-1h68 replication was also monitored in tumor cell lines of different origins 
which were characterized as non-responders to GLV-1h68 by Worschech et al. 
(2009). Worschech et al. described poor replication of GLV-1h68 in the cell lines 
SiHa (cervical squamous cell carcinoma) and NCI-H1299 (breast cancer) 24 hpi 
with GLV-1h68 in vitro and non-responding of HT29 (colorectal carcinoma) 
tumors in a xenograft mouse model after intravenous injection of GLV-1h68 
(Worschech et al., 2009). Other than expected we found a quite obvious 
increase in viral yield 24 hpi in our experiments, increasing further until viral 
replication stagnated 72 hpi in NCI-H1299 cells and 96 hpi in SiHa and HT29 
cells. This discrepancy might result from differences in cell culture conditions or 
preparation of the virus stocks used in here. In order to come to a common 
understanding of which tumor cell lines indeed exhibit a primary resistance to 
GLV-1h68-based oncolysis a repetition of the xenograft animal experiments has 
to be undertaken. However, animal experimentation was beyond the scope of 
this doctoral thesis and has to be done in separate work. 
 
Oncolytic efficacy of MeV and VACV differed a lot regarding cell killing 
efficiencies 
The most important step of our investigations was to monitor and compare the 
oncolytic efficacy of MeV-SCD and GLV-1h68. Therefore, we performed two 
well established cytotoxicity assays, the SRB and the LDH assay. In SRB 
assay, cell death was measured as cell mass reduction in percent compared to 
mock-infected control. In LDH assay, increase in LDH compared to mock-
infected cells was a marker for cell lysis. To classify tumor cells which were 
resistant to virotherapeutic treatment we developed a resistance definition for 
both MeV and VACV. A tumor cell line was declared to be primary resistant to 
MeV-SCD/ GLV-1h68 oncolysis when the remaining cell mass was above 50% 
of the control at MOI 1 (MeV-SCD)/ MOI 0.1 (GLV-1h68) at 96 hpi. 
As a result, A673 and BRZ cells were completely eradicated 96 hpi with MeV-
SCD. SRH cells reacted resistant (more than 50% remaining cell mass at 96 
hpi) and SCOS cells strongly resisted treatment (more than 75% remaining cell 
mass at 96 hpi) with MeV-SCD. LDH release in BRZ cells decreased with 
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addition of higher 5-FC concentrations which we had expected to be exactly the 
other way round. As 5-FC is suspected to negatively interact with viral 
replication, the addition of 5-FC was postponed to 48 hpi (instead of 3 hpi) to 
extend the process of “unaffected” viral replication. Several authors found out 
that the success of suicide gene therapy is grossly dependent on the right 
timing of prodrug addition (Seo et al., 2005; Ungerechts et al., 2007; 
Ungerechts et al., 2010; Wildner et al., 1999). Thus, Ungerechts et al. 
(2007/2010) suggested the time point of maximal viral replication as being the 
best for the prodrug addition. Despite non-specific results in LDH assay, the 
syncytial morphology, a typical cytopathic effect (CPE) post MeV infection 
(Blechacz et al., 2006; Peng et al., 2001; Phuong et al., 2003) followed by 
apoptotic or non-apoptotic cell death, morphological aspects in phase contrast 
microscopy and SRB data of both A673 and BRZ cells were evidence of 
successful tumor cell killing in vitro. 
In order to enhance the oncolytic effect of MeV-SCD in SRH and SCOS cells, 
our experiment was stretched to 144 hpi to allow effective replication of MeV-
SCD. The maximal dose of MOI 1 was increased to MOI 10 plus the highest 
concentration of 1 mM 5-FC to raise the number of viral particles per cell. As a 
result, SRH cells were totally eradicated 144 hpi with MeV-SCD at MOI 10 plus 
1 mM 5-FC. SCOS cells still were found to be resistant, despite this extensive 
virotherapeutic treatment including usage of the vector-encoded suicide gene 
function. More than 50% of the SCOS cell mass stayed attached at the end of 
the experiment. Yet we had to consider the possible damage after 
administration of MeV-SCD at MOI 10 to healthy tissue in vivo. Such a high 
level of viral load could cause serious side effects in healthy tissues as there 
could be too few tumor cells as a target for the viral particles. Instead of killing 
cancer cells, viruses might also attack healthy cells. Avoiding high MOIs, GLV-
1h68 was chosen to overcome SCOS resistance to MeV-SCD. Of note, SCOS 
could not be completely eradicated by GLV-1h68 but were reduced to 35% of 
control 96 hpi at MOI 1. 
Human sarcomas had already been successfully treated with virotherapy (He et 
al.; 2012) but there have also been unsuccessful investigations (Cripe et al., 
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2001). He S. et al. (2012) lately published their research on human sarcoma cell 
lines treated with GLV-1h68 in vitro and in vivo (single intratumoral injection of 
GLV-1h68 into HT-1080 fibrosarcoma xenografts) which showed transgene 
expression in all tumor cell lines and cytotoxicity to three of four tested cell lines. 
There was no evidence of viral spread to healthy tissue in the xenograft model 
and near-complete reduction of the tumors at 28 days post infection (dpi) (He et 
al., 2012). 
Therefore, in this work the resistant sarcoma cell lines and the before 
mentioned non-responding tumor cell lines (Worschech et al., 2009) were 
treated with an armed VACV. Thereby, we set out to come to a more 
comprehensive picture on the effectiveness of virotherapeutic approaches 
(including employment of suicide gene armed vector variants) in the treatment 
of chemotherapy-resistant sarcomas. Different armed VACV encoding Cytosine 
Deaminase (CD) have already been applied in vitro and in vivo (Gnant et al., 
1999; McCart et al., 2000). Moreover Mc Cart et al. (2000) could show that the 
oncolytic efficacy of VACV alone was improved by the insertion of CD and the 
addition of 5-FC. As 5-FU is known to reduce the protein-, DNA- and RNA-
production of the host cell to a minimum and additionally provides the 
advantageous “bystander effect”, it makes GLV-1h95 a promising cytotoxic tool. 
Moreover, 5-FC addition would allow to reduce the MOI, potentially decreasing 
therapy limiting viral side effects to a minimum. When GLV-1h95 was applied at 
MOI 1 plus 1 mM 5-FC this could not improve cell mass reduction 96 hpi in 
comparison with GLV-1h68 because cell mass had already been reduced to a 
minimum with GLV-1h68, but could definitely reduce cell mass to a higher 
extent than GLV-1h68 at the lower MOI 0.1 plus 1mM 5-FC. GLV-1h95 even 
reduced cell mass of the resistant sarcoma cell line SCOS to less than 25% of 
control at MOI 1 and 1 mM 5-FC. Thus, the suicide gene VACV-based 
virotherapeutic GLV-1h95 was demonstrated to be most effective in the 
challenging context of highly chemotherapy-resistant human sarcomas. 
Regarding the in vivo application of GLV-1h68 in previous studies, the ability of 
GLV-1h68 to lyse tumor cells and cause regression of human xenograft tumors 
has already been shown and led to a significant reduction of primary tumors 
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induced by PC-3 and DU-145-cells in nude mice, regression of human prostate 
tumors (Gentschev et al., 2010), solid breast tumors (Zhang et al., 2007), HCC 
(hepatocellular carcinoma) (Gentschev et al., 2011), malignant pleural 
mesothelioma (Kelly et al., 2008), anaplastic thyroid carcinoma (Lin et al., 
2007), canine mammary carcinoma (Gentschev et al., 2009; Gentschev et al., 
2010) and human pancreatic tumors (Yu et al., 2009). Furthermore, Worschech 
et al. (2009) achieved to reduce several species of xenograft tumors after GLV-
1h68 infection which they called in vivo responders (Worschech et al., 2009). 
Beyond these findings, Gentschev et al. and Kelly et al. (2009) showed that 
GLV-1h68 was able to reduce metastatic lymph nodes in a tumor xenograft 
model caused by a PC-3 induced prostate carcinoma (Kuriyama et al., 1998) 
and in an immunocompetent animal model of a metastatic melanoma (Kelly et 
al., 2009). In the phase I trial of Park et al. (2008) the poxvirus JX-594 was 
found to spread throughout the body to distant metastases (Park et al., 2008). 
As there have not been yet any evaluations of GLV-1h95 in vivo like it was done 
already with GLV-1h68, we suggest further investigation of GLV-1h95 in vitro 
and in vivo to precisely evaluate its oncolytic efficacy and possible superiority in 
comparison to non-armed virotherapeutic vector generations. 
 
Safety investigation in PHHs revealed an excellent safety profile at low 
MOIs 
Regarding the safety of virotherapeutics, we wanted to investigate if our 
oncolytic viruses exert any toxicity on healthy/non-malignant cells. Therefore, 
we infected primary human hepatocytes (PHHs) with increasing concentrations 
of GLV-1h68 from MOI 0.01 to MOI 10. Fluorescence microscopy showed few 
infected cells at MOI 0.1 96 hpi and widespread GFP expression at MOI 1 at 72 
- 96 hpi indicating that most of the cells were infected with GLV-1h68 at MOI 1 
but only few cells were infected after treatment with MOI 0.1. Confirming this 
data, cell mass infected with MOI 1 was reduced to 50% of control whereas cell 
mass infected with MOI 0.1 was not reduced in our cytotoxicity testing. When 
we had a closer look on the infected cell layers at MOI 1 using phase contrast 
microscopy, we got the impression that most of the cells indeed were infected 
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and expressed GFP but they were still well attached to the bottom of the plates. 
So the question was how to differentiate between simply infected and dead 
cells. The problem is that the SRB assay only displays cell mass reduction but 
no cell death mechanisms not leading to cell lysis or cell mass reduction. The in 
vitro finding of virus infection in healthy cells could also be shown by Zhang et 
al. (2009), who detected very low GLV-1h68 concentrations in healthy liver, 
kidney and heart tissue and higher concentrations in the lung tissue of nude 
mice after injection of GLV-1h68 (Zhang et al., 2009). Contrary to this, Shu-Fu et 
al. (2007) showed that GLV-1h68 could replicate within tumor cells but not in 
non-malignant healthy cells (Shu-Fu et al., 2007) and Lin et al. (2008) showed 
that GLV-1h68, injected into healthy tissue, could not be retraced at 10 dpi and 
no toxic side effects could be detected in vivo (Lin et al., 2008). 
JX-594, another engineered oncolytic poxvirus, has also been tested with 
regard to its safety profile and gives an idea of possible virus-related side 
effects on normals tissues. In a phase I study in patients with HCC, grade 1 and 
2 flu-like symptoms were observed, dose-related hypotension, hyperbili-
rubinaemia, increase in monocytes and eosinophils, thrombocytopenia and 
neutropenia also occurred. None of the patients died treatment related and 
some cases of stable disease and even objective tumor response were 
observed (Park et al., 2008). Park et al. (2008) called the safety of JX-594 
“acceptable”. A clinical phase I trial currently taking place at the Royal Marsden 
Hospital, Surrey, UK (EudraCT-Nr. 2007-004228-18), so far revealed no dose 
limiting cytotoxicity and especially no singificant elevation of transaminases was 
detected after intravenous application of GLV-1h68. Moreover, VACV has 
already demonstrated an acceptable safety profile in humans, since it was given 
to millions of people as a smallpox vaccine.  
The outstanding safety profile of MeV has also been confirmed many times 
before (Blechacz et al., 2006; Springfeld et al., 2006). In this line, investigation 
of MeV-hCEA only displayed minimal cytopathic effects on healthy cells (Peng 
et al., 2002). 
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In summary we detected significant GFP expression and cell mass reduction in 
our in vitro trials in PHH only at high MOI 1. One explanation for our results of 
PHH cell damage at high MOI might be the lack of an integrated immune 
system in the in vitro cell cultures in contrast to clinical and preclinical in vivo 
testing of GLV-1h68. The immune system especially in healthy tissues is 
normally able to get rid of the viruses attacking healthy cells. Our in vitro results 
on PHH thereby do reflect the “artifical” conditions being quite often associated 
with cell culture research. Accordingly, it is not surprising that our in vitro 
findings could not be confirmed by current clinical research in which elevated 
transaminases are observed quite rarely and are not clearly related to a direct 
virotherapeutic effect (our unpublished results). 
As the ultimate goal in virotherapy should be complete cytoreduction, the higher 
cytotoxic effect of GLV-1h95 compared to GLV-1h68, even though it was only a 
moderate difference, is stimulating to investigate also GLV-1h95 in further 
clinical trials. In addition, further investigations using a combination of different 
virotherapeutics e.g. VACV and MeV should be considered to enhance MeV 
cytotoxicity and to find synergistic effects, especially in cancer patients 
exhibiting primary resistance to virotherapeutic treatment of either viro-
therapeutic. This approach already has been successfully tested preclinically by 
Le Boef et al. (2010) concurrently using a VACV and a vesicular stomatitis virus 
(VSV) and is now being tested also in our laboratory. Furthermore, the 
combination of oncolytic viruses and radiotherapy has been successfully tested 
preclinically (Hanna et al., 1997; Kievit et al., 1999; Pederson et al., 1997; 
Pederson et al., 1998; Stackhouse et al., 2000; Xing et al., 2009; Zhang et al., 
2003) as it has also been done with oncolytic viruses and chemotherapy, which 
is known to lead to a better tumor regression in contrast to only using one of 
them (Mahoney et al., 2010; Yu et al., 2009). In order to enhance oncolytic 
efficacy, these approaches also should be expedited. Indeed, there is an 
actively recruiting clinical trial (Phase I Trial Of Attenuated Vaccinia Virus (GL-
ONC1) Delivered Intravenously With Concurrent Cisplatin and Radiotherapy in 
Patients With Locoregionally Advanced Head and Neck Carcinoma; 
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ClinicalTrials.gov Identifier: NCT01584284) in which the GMP-produced version 
of GLV-1h68 (called GL-ONC1) is tested in conjunction with radiotherapy. 
For further investigations we propose to evaluate the oncolytic potential of GLV-
1h68 in a preclinical syngeneic animal model of peritoneal carcinosis. The well-
established WAG/Rij rat animal model of the peritoneal carcinosis (Pelz et al., 
2005; Pelz et al., 2006; Zedeck et al., 1974;) is available for the treatment of 
syngeneic CC531s induced peritoneal carcinosis (Pelz et al., 2005; Pelz et al., 
2006; Zedeck et al., 1974;). Intraperitoneally injected CC531s cells causing a 
peritoneal tumor mass will afterwards be treated with both peritonectomy (state-
of-the-art surgical intervention) and intraperitoneal instillation of GLV-1h68 
ideally leading to a complete cytoreduction which significantly would improve 
prognosis and overall survival. Debulking surgery combined with HIPEC already 
lengthened survival of peritoneal carcinosis patients (Königsrainer et al., 2008; 
Verwaal et al., 2003). Another well characterized xenograft model of the 
peritoneal carcinosis in athymic mice (Hasegawa et al., 2006; Peng et al., 2002; 
Yoneda et al., 1998) caused by intraperitoneal application of SKOV3ip.1 cells 
(Yoneda et al., 1998) constitutes an alternative preclinical model which also 
could be useful for preclinical in vivo trials. Tumor volume could be monitored 
using micro-PET-MRT-monitoring or immune-scintigraphy at different time 
points throughout the trial as it has already been done by several other authors 
(Pichler et al., 2008; Pross et al., 2001). 
Bridging the gap between animal in vivo trials and phase I studies in humans, 
the concept of using human Precision Cut Tumor Tissue Slices (PCTTS) which 
was established by Zimmermann et al. (2009) in our laboratory has already 
been successfully tested in terms of infection, replication and tumor cell killing 
with human HCC/liver tissues and might be a helpful tool for the preclinical 
selection of a potentially effective virotherapeutic in a “customized” setting. Last 
but not least, Single Cell Suspensions (SCS) of human tumor material display 
another effective method to pre-evaluate oncolytic viral vectors before applying 
them in vivo. In 2012, Prof. U.M. Lauer et al. started a phase I/II trial “A Study of 
GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal 
Carcinomatosis” (ClinicalTrials.gov Identifier: NCT01443260), treating 
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peritoneal carcinosis by virotherapy at the Medical University Hospital Tübingen 
with the hope to find an effective therapeutic against this deleterious form of 
cancer. 
Summing up our findings, MeV-SCD, GLV-1h68 and GLV-1h95 were 
investigated in vitro with regard to their ability of infection, replication behaviour 
and oncolysis as potential virotherapeutics in the fight against cancer. We found 
out that MeV-SCD was able to kill primarily therapy-resistant sarcoma cell lines 
expressing high levels of CD46 but failed to efficiently kill the latter expressing 
low levels of CD46. GLV-1h68 however was able to kill primarily therapy-
resistant sarcoma cell lines, the peritoneal carcinosis causing cell lines CC531s 
and SKOV3ip.1 and all the cell lines denominated as ‘in vivo non-responders’ in 
prior work by Worschech et al. (2009). The SCOS cells, which were found to be 
highly resistant to MeV-SCD oncolysis, also resisted GLV-1h68 treatment albeit 
to a lower extent. The armed vector GLV-1h95 finally led to massive cell mass 
reduction also of SCOS cells. The additional effect of the suicide gene therapy 
with GLV-1h95 and 5-FC especially became obvious in trials with low MOI 0.1. 
Healthy PHHs were demonstrated to be infected by GLV-1h68 but stayed alive 
and mostly unaffected at low MOI 0.1. 
Therefore, our virotherapeutic approaches should be short-listed to fight 
especially against highly chemotherapy-resistant cancer entities, such as 
peritoneal carcinosis and sarcomas, in order to overcome current severe 
therapy resistances. 
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5 Summary/Zusammenfassung 
Resistances to common therapy approaches in cancer therapy are a worldwide 
problem today. Virotherapy is one of the novel anti-cancer strategies currently 
being investigated in preclinical experiments and clinical trials. Virotherapy is 
based on attenuated, replication-competent oncolytic viruses which selectively 
infect, replicate in and kill tumor cells without significantly harming healthy 
tissue. To advance the inherited oncolytic effect of viruses, transgenes like anti-
angiogenic, immuno-stimulatory or suicide genes were inserted into the viral 
genome. 
 
For our examinations we chose two genetically modified viral vector systems, 
MeV (MeV-SCD) and VACV (GLV-1h68/GLV-1h95), which hold an outstanding 
safety profile and recently have entered extensive clinical testing as state-of-
the-art virotherapeutics. Both vector systems encode for marker genes and 
were armed with the suicide gene SCD which converts the non-toxic prodrug 5-
FC into the common chemotherapeutic 5-FU. 
 
MeV-SCD, GLV-1h68 and GLV-1h95 were investigated with regard to their 
ability of infection, replication behaviour and oncolysis in vitro as potential 
virotherapeutics in the fight against cancer. Summing up our findings we could 
demonstrate that MeV-SCD was able to kill primarily therapy-resistant sarcoma 
cell lines expressing high levels of CD46 but failed to kill the latter expressing 
low levels of CD46. CD46 is known to be the entrance molecule for MeV on 
tumor cells. GLV-1h68 however was able to kill primarily therapy-resistant 
sarcoma cell lines, the peritoneal carcinosis causing cell lines CC531s and 
SKOV3ip.1 and also all the cell lines called ‘in vivo non-responders’ by 
Worschech et al. (2009). The SCOS cells, which were highly resistant to MeV-
SCD, also resisted GLV-1h68 treatment to a lower extent. The armed vector 
GLV-1h95 finally led to massive cell mass reduction of SCOS cells. The 
additional effect of the suicide gene therapy with GLV-1h95 and 5-FC especially 
became obvious in our experiments with low MOI 0.1. Healthy PHHs were 
infected by GLV-1h68 but stayed mostly unaffected at MOI 0.1. Therefore, our 
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virotherapeutics should be short-listed to fight against peritoneal carcinosis and 
sarcomas in order to overcome current therapy resistances. 
 
We suppose that future preclinical investigations should take place in the well-
established WAG/Rij rat animal model of the peritoneal carcinosis (Zedeck et 
al., 1974; Pelz et al., 2005; Pelz et al., 2006) and further studies should be done 
using primary human tumor material like Single Cell Suspensions (SCS) or 
Precision Cut Tumor Tissue Slices (PCTS) to confirm our findings in vivo. 
 
In der Krebstherapie auftretende primäre Therapie-Resistenzen stellen weltweit 
ein schwerwiegendes Problem dar. Bei der Virotherapie handelt es sich um 
eine neuartige Therapie-Strategie, die momentan präklinisch und klinisch 
erprobt wird. Diese Methode basiert auf attenuierten replikationskompetenten 
onkolytischen Viren, die selektiv Tumorzellen infizieren, intrazellulär replizieren 
und die Tumorzellen abtöten, ohne umliegendes gesundes Gewebe zu 
schädigen. Um die intrinsische onkolytische Aktivität der eingesetzten Viren 
weiter zu verbessern, wurden Transgene wie Antiangiogenese-, 
Immunstimulations- und Suizid-Gene in das Genom verschiedener Viren 
eingefügt. 
 
In dieser Dissertation wurden zwei genetisch modifizierte virale Vektorsysteme, 
MeV (MeV-SCD) und VACV (GLV-1h68/GLV-1h95) verwendet, die ein 
hervorragendes Sicherheitsprofil aufweisen und derzeit in verschiedenen Phase 
I/II Studien extensiv gestetet werden. Die Genome von VACV und MeV wurden 
dahingehend rekombinant modifiziert, dass diese Markergene und das 
Suizidgen SCD enthalten. SCD hat die Funktion, den primär nicht-toxischen 
Wikrstoff 5-FC in das gut bekannte Chemotherapeutikum 5-FU umzuwandeln, 
welches dann zusätzlich zur Zelltötung beiträgt. Somit kann in der Umgebung 
erfolgreich infizierter Tumorzellen eine SCD-basierte lokale Chemotherapie 
erfolgen. 
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MeV-SCD, GLV-1h68 und GLV-1h95 als potentielle Virotherapeutika wurden im 
Hinblick auf ihre Fähigkeit Tumorzellen zu infizieren, unter Inanspruchnahme 
des zellulären Biosyntheseapparates zu replizieren und die Tumorzellen 
letztlich zu töten, untersucht. 
 
Unsere Ergebnisse zeigen, dass MeV-SCD primär Therapie-resistente 
Sarkomzelllinien in Abhängigkeit von deren CD46 Rezeptor-Expression töten 
können, wobei CD46 den Eintrittsmechanismus von MeV in Tumorzellen 
darstellt. Jene Sarkomzelllinien, die eine hohe CD46 Expression aufweisen, 
wurden besonders gut abgetötet, während Zelllinien mit niedrigerer CD46 
Expression durch die virotherapeutische Behandlung mit MeV-SCD weniger 
geschädigt wurden. Das VACV-basierte Virotherapeutikum GLV-1h68 hingegen 
konnte alle primär Therapie-resistenten Sarkomzelllinien abtöten und war 
darüber hinaus fähig, die beiden Peritonealkarzinose-verursachenden Zelllinien 
CC531s und SKOV3ip.1 abzutöten. Auch die zuvor als „in vivo non-responder“ 
bezeichneten Zelllinien von Worschech et al. (2009) konnten im Rahmen dieser 
Arbeit unter in vitro Bedingungen erfolgreich abgetötet werden. Lediglich die am 
stärksten resistente Sarkomzelllinie SCOS konnte nur in der Kombination aus 
GLV-1h95 und gleichzeitig verabreichter prodrug 5-FC hinreichend abgetötet 
werden. Die zusätzliche Suizidgenfunktion des VACV GLV-1h95 konnte in 
unseren Experimenten nur bei der niedrigen MOI 0.1 eine onkolytische 
Effektivitätssteigerung bewirken, da bei höheren MOIs der direkte onkolytische 
Effekt zu dominant war als dass noch ein zusätzlicher Suizidgeneffekt hätte 
zum Tragen kommen können. Gesunde primäre humane Hepatozyten 
überlebten die Behandlung mit GLV-1h68 bei niedriger „Viruslast“ (MOI 0.1), bei 
höherer Viruslast (MOI 1) zeigten sich ebenfalls ausgeprägte zytotoxische 
Effekte, was allerdings weitestgehend auf die artifiziellen Verhältnisse der in 
vitro Primärzellkultur zurückgeführt werden muss, da sich in den bisherigen 
Klinischen Versuchen keine Korrelate für eine signifikante Leberzellschädigung 
finden lassen. 
Aufgrund unserer vielversprechenden Ergebnisse postulieren wir, dass die von 
uns präklinisch getesteten Virotherapeutika sowohl in dem etablierten WAG/Rij 
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Ratten Model der Peritonealkarzinose als auch an primärem humanen 
Tumormaterial in Form von Zellvereinzelungen und primären humanen 
Gewebekulturschnitten getestet werden sollen, um die weitere klinische 
Entwicklung dieser beiden Virotherapeutika-Familien weiter voranzutreiben.  
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6 Abbreviations 
 
APS  ammonium persulfate 
ATCC  American Type Culture Collection 
BSA  bovine serum albumin 
CD46  cluster of differentiation 46 receptor 
CD150 cluster of differentiation 150 receptor 
CMC  Carboxymethylcellulose sodium salt 
CPE  cytopathic effect 
ctrl.  control 
ddH2O double-distilled water 
DMEM Dulbecco`s modified Eagle medium 
DMEM-2 DMEM supplemented with 2% FBS 
DMEM-10 DMEM supplemented with 10% FBS 
DMSO Dimethylsulfoxide 
DNA  desoxyribonucleic acid 
dpi  days post infection 
dUMP  deoxyuridine monophosphate 
ECL  ECL detection reagent 1+2 
EDTA  Ethylenediaminetetraacetic acid 
eGFP  enhanced green fluorescent protein 
FACS  fluorescence activated cell sorting 
FBS  fetal bovine serum 
GFP  green fluorescent protein 
GLV-1h68 vaccinia vaccine virus 
gusA  gene which encodes for β-glucoronidase 
HA  hemagglutinin 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIPEC Hypertherme intraperitoneale Chemoperfusion 
hpi  hours post infection 
HPLC  high performance liquid chromatography 
HRP  horseradish peroxidase 
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i.p.  intraperitoneal 
kb  kilo base 
kDa  kilo Dalton 
lacZ  gene which encodes for β-galactosidase 
ld  leader 
LDH  lactate dehydrogenase 
LIVP  Lister strain from the Institute for Research on Viral Preparations 
MeV  measles virus 
MeV-GFP measles virus including the leader sequence green fluorescence 
protein 
MeV-SCD measles virus including the leader sequence Super Cytosine 
Deaminase 
MOI  multiplicity of infection 
NAD+  Nicotinadenindinukleotide ox 
NADH  Nicotinadenindinukleotide red 
NEAA  non-essential amino acids 
NP40  Nonidet P-40, nonionic detergent 
NR  non-responder 
OD  optical density 
PBS  phosphate buffered saline 
PCTTS Precision Cut Tumor Tissue Slices 
PFA  paraformaldehyde 
PFU  plaque forming unit 
PHH  primary human hepatocytes 
pos.  positive 
PVDF  polyvinylidene difluoride 
RNA  ribonucleic acid 
RNAP  RNA polymerase 
rpm  rounds per minute 
RT  room temperature 
RUC-GFP Renilla Luciferase green fluorescent protein fusion gene 
SCD  Super Cytosine Deaminase 
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SCS  Single Cell Suspension 
SD  standard deviation 
SDS  Sodiumdodecylsulfate 
SEM  standard error of the mean 
SLAM  Human signalling lymphocyte activation molecule 
SRB  sulforhodamine B 
TBS  Tris-buffered saline 
TBS-T TBS-Triton = TBS+ 0.02% Triton X-100 
TBS-Tween Tris.buffered saline containing Tween 20 
TCA  trichloracetic acid 
TCID50 50% end point dilution assay 
TEMED tetramethylenediamine (C6H12N2) 
Tris  trishydroxymethylaminomethane 
Triton X-100 nonionic detergent, Octylphenol ethylene oxide condensate 
TS  thymidylate synthetase 
UPRT  uracil phosphoribosyltransferase 
UV  ultra violet 
X-Gal  5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
YCD  yeast (Saccharomyces cerevisiae) Cytosine Deaminase 
YUPRT yeast (Saccharomyces cerevisiae) uracil 
phosphoribosyltransferase 
5-FC  5-fluorocytosine 
5-FU  5-fluorouracil 
5-FdUMP 5-fluoro-deoxyuridine monophosphate 
5-FUMP 5-fluorouridine monophosphate 
5-FUTP 5-fluorouridine triphosphate 
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